Sorrento Therapeutics (SRNE) 10-K 1 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 21, 2014	Jun. 28, 2013
Document And Entity Information [Abstract]	'	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Trading Symbol	'SRNE	'	'
Entity Registrant Name	'Sorrento Therapeutics, Inc.	'	'
Entity Central Index Key	'0000850261	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Voluntary Filers	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Common Stock, Shares Outstanding	'	23,028,101	'
Entity Public Float	'	'	$51,715,293

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$31,666,732	$5,091,312
Grants and accounts receivable, net	394,246	79,760
Prepaid expenses and other	570,956	80,918
Total current assets	32,631,934	5,251,990
Property and equipment, net	2,439,853	1,480,989
Intangibles, net	33,321,192	'
Goodwill	24,040,966	'
Other	148,058	48,625
Total assets	92,582,003	6,781,604
Current liabilities:	'	'
Accounts payable	2,153,880	439,533
Accrued payroll and related	1,663,518	77,744
Current portion of deferred compensation	903,763	'
Accrued expenses	384,640	66,896
Current portion of debt	373,930	'
Total current liabilities	5,479,731	584,173
Long-term liabilities:	'	'
Long-term debt	4,430,864	'
Deferred compensation	1,497,004	'
Deferred rent	81,242	'
Deferred tax liabilities	14,248,000	'
Accrued other	36,031	'
Commitments and contingencies (Note 8)	'	'
Stockholders' equity:	'	'
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding	'	'
Common stock, $0.0001 par value; 750,000,000 shares authorized and 23,028,100 and 12,004,687 shares issued and outstanding at December 31, 2013 and 2012, respectively	2,303	1,200
Additional paid-in capital	99,668,390	17,146,530
Deficit accumulated during the development stage	-32,861,562	-10,950,299
Total stockholders' equity	66,809,131	6,197,431
Total liabilities and stockholders' equity	$92,582,003	$6,781,604

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	23,028,100	12,004,687
Common stock, shares outstanding	23,028,100	12,004,687

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		95 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenues:	'	'	'
Grant	$451,773	$583,774	$2,023,846
Sales and services	8,375	'	8,375
Collaboration and reimbursable research and development costs	'	'	223,453
Total revenues	460,148	583,774	2,255,674
Operating costs and expenses:	'	'	'
Cost of sales and services revenues	4,440	'	4,440
Research and development	9,016,623	3,830,404	17,219,949
Acquired in-process research and development	5,985,542	'	5,985,542
General and administrative	6,317,157	1,605,978	10,888,550
Intangible amortization	804,070	'	804,070
Total operating costs and expenses	22,127,832	5,436,382	34,902,551
Loss from operations	-21,667,684	-4,852,608	-32,646,877
Interest expense	-253,194	'	-253,194
Interest income	9,615	7,300	38,509
Net loss	($21,911,263)	($4,845,308)	($32,861,562)
Net loss per share- basic and diluted	($1.46)	($0.42)	'
Weighted average number of shares during the period- basic and diluted	15,045,711	11,405,042	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)

Total

IgDraSol, Inc. [Member]

Sherrington Pharmaceuticals, Inc. [Member]

Concortis Biosystems, Corp. [Member]

June 2009 [Member]

September 2009 [Member]

March 2013 [Member]

October 2013 [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

Stockholder Note Receivable [Member]

Deficit Accumulated During Development Stage [Member]

IgDraSol, Inc. [Member]

Sherrington Pharmaceuticals, Inc. [Member]

Concortis Biosystems, Corp. [Member]

June 2009 [Member]

September 2009 [Member]

March 2013 [Member]

October 2013 [Member]

IgDraSol, Inc. [Member]

Sherrington Pharmaceuticals, Inc. [Member]

Concortis Biosystems, Corp. [Member]

June 2009 [Member]

September 2009 [Member]

March 2013 [Member]

October 2013 [Member]

Balance at Jan. 25, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Jan. 25, 2006

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for $400 cash to founders

400

'

'

'

'

'

'

'

408

'

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

'

'

Issuance of common stock for $400 cash to founders, shares

'

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-75,801

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-75,801

Balance at Dec. 31, 2006

-75,401

'

'

'

'

'

'

'

408

'

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

'

-75,801

Balance, shares at Dec. 31, 2006

'

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-16,302

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-16,302

Balance at Dec. 31, 2007

-91,703

'

'

'

'

'

'

'

408

'

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

'

-92,103

Balance, shares at Dec. 31, 2007

'

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-25,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-25,745

Balance at Dec. 31, 2008

-117,448

'

'

'

'

'

'

'

408

'

'

'

'

'

'

'

-8

'

'

'

'

'

'

'

'

-117,848

Balance, shares at Dec. 31, 2008

'

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of restricted common stock for $291 cash to consultants in March

291

'

'

'

'

'

'

'

30

'

'

'

'

'

'

'

261

'

'

'

'

'

'

'

'

'

Issuance of restricted common stock for $291 cash to consultants in March, shares

'

'

'

'

'

'

'

'

296,155

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for $10 cash and a $30 note to consultants in March

10

'

'

'

'

'

'

'

4

'

'

'

'

'

'

'

36

'

'

'

'

'

'

'

-30

'

Issuance of common stock for $10 cash and a $30 note to consultants in March, shares

'

'

'

'

'

'

'

'

40,775

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock to former QuikByte stockholders in connection with the Merger

100,386

'

'

'

'

'

'

'

44

'

'

'

'

'

'

'

100,342

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash

'

'

'

'

2,274,001

2,000,000

'

'

'

'

'

'

236

179

'

'

'

'

'

'

2,273,765

1,999,821

'

'

'

'

Issuance of common stock to former QuikByte stockholders in connection with the Merger, shares

'

'

'

'

'

'

'

'

442,958

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, shares

'

'

'

'

'

'

'

'

'

'

'

'

2,360,611

1,785,375

'

'

'

'

'

'

'

'

'

'

'

'

Costs associated with the Merger

-168,767

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-168,767

'

'

'

'

'

'

'

'

'

Stock-based compensation

54,524

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

54,524

'

'

'

'

'

'

'

'

'

Net loss

-942,266

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-942,266

Balance at Dec. 31, 2009

3,200,731

'

'

'

'

'

'

'

901

'

'

'

'

'

'

'

4,259,974

'

'

'

'

'

'

'

-30

-1,060,114

Balance, shares at Dec. 31, 2009

'

'

'

'

'

'

'

'

9,003,367

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Collection of note receivable

30

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

'

Issuance of common stock for cash

3,440,495

'

'

'

'

'

'

'

102

'

'

'

'

'

'

'

3,440,393

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, shares

'

'

'

'

'

'

'

'

1,028,686

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

250,954

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

250,954

'

'

'

'

'

'

'

'

'

Net loss

-1,808,386

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,808,386

Balance at Dec. 31, 2010

5,083,824

'

'

'

'

'

'

'

1,003

'

'

'

'

'

'

'

7,951,321

'

'

'

'

'

'

'

'

-2,868,500

Balance, shares at Dec. 31, 2010

'

'

'

'

'

'

'

'

10,032,053

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repurchase of common stock

-43

'

'

'

'

'

'

'

-5

'

'

'

'

'

'

'

-38

'

'

'

'

'

'

'

'

'

Repurchase of common stock, shares

'

'

'

'

'

'

'

'

-44,166

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options

13,125

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

13,124

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options, shares

'

'

'

'

'

'

'

'

6,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash

1,971,001

'

'

'

'

'

'

'

50

'

'

'

'

'

'

'

1,970,951

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, shares

'

'

'

'

'

'

'

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction of stock issuance costs accrued in December 2010

80,039

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

80,039

'

'

'

'

'

'

'

'

'

Stock-based compensation

298,034

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

298,034

'

'

'

'

'

'

'

'

'

Net loss

-3,236,491

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-3,236,491

Balance at Dec. 31, 2011

4,209,489

'

'

'

'

'

'

'

1,049

'

'

'

'

'

'

'

10,313,431

'

'

'

'

'

'

'

'

-6,104,991

Balance, shares at Dec. 31, 2011

'

'

'

'

'

'

'

'

10,493,887

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options

36,092

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

36,091

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options, shares

'

'

'

'

'

'

'

'

10,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash

5,934,031

'

'

'

'

'

'

'

150

'

'

'

'

'

'

'

5,933,881

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash, shares

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

863,127

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

863,127

'

'

'

'

'

'

'

'

'

Net loss

-4,845,308

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-4,845,308

Balance at Dec. 31, 2012

6,197,431

'

'

'

'

'

'

'

1,200

'

'

'

'

'

'

'

17,146,530

'

'

'

'

'

'

'

'

-10,950,299

Balance, shares at Dec. 31, 2012

'

'

'

'

'

'

'

'

12,004,687

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options

17,145

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

17,144

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with the exercise of stock options, shares

'

'

'

'

'

'

'

'

7,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock with assignment agreement

40,000

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

39,999

'

'

'

'

'

'

'

'

'

Issuance of common stock for cash

'

'

'

'

'

'

6,354,409

31,346,960

'

'

'

'

'

'

143

477

'

'

'

'

'

'

6,354,266

31,346,483

'

'

Issuance of common stock for cash, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,426,406

4,772,500

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in connection with merger and acquisition

'

27,811,429

1,697,600

11,295,173

'

'

'

'

'

301

20

133

'

'

'

'

'

27,811,128

1,697,580

11,295,040

'

'

'

'

'

'

Issuance of common stock in connection with merger and acquisition, shares

'

3,006,641

'

1,331,978

'

'

'

'

'

3,006,641

'

1,331,978

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock with assignment agreement, shares

'

'

'

'

'

'

'

'

10,000

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock warrants in connection with loan and security agreement

214,680

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

214,680

'

'

'

'

'

'

'

'

'

Issuance of common stock for convertible note holders

1,856,832

'

'

'

'

'

'

'

26

'

'

'

'

'

'

'

1,856,806

'

'

'

'

'

'

'

'

'

Issuance of common stock for convertible note holders, shares

'

'

'

'

'

'

'

'

256,119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock in lieu of cash legal fees

100,001

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

Issuance of common stock in lieu of cash legal fees, shares

'

'

'

'

'

'

'

'

12,469

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation

1,788,734

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,788,734

'

'

'

'

'

'

'

'

'

Net loss

-21,911,263

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-21,911,263

Balance at Dec. 31, 2013

$66,809,131

'

'

'

'

'

'

'

$2,303

'

'

'

'

'

'

'

$99,668,390

'

'

'

'

'

'

'

'

($32,861,562)

Balance, shares at Dec. 31, 2013

'

'

'

'

'

'

'

'

23,028,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Consolidated_Statements_of_Sto1

Consolidated Statements of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2009	Dec. 31, 2009	Dec. 31, 2013	Dec. 31, 2013
					IgDraSol, Inc. [Member]	Sherrington Pharmaceuticals, Inc. [Member]	Concortis Biosystems, Corp. [Member]	June 2009 [Member]	September 2009 [Member]	March 2013 [Member]	October 2013 [Member]
Proceeds from issuance of note to consultants	'	'	'	$30	'	'	'	'	'	'	'
Issuance of common stock per share	$4	$4	$3.50	'	$9.25	$8.48	$8.48	$0.98	$1.12	$4.50	$7.25
Common stock issuance cost	$65,969	$28,999	$159,905	'	'	'	'	$25,999	'	$64,086	$3,253,770

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		95 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Operating activities	'	'	'
Net loss	($21,911,263)	($4,845,308)	($32,861,562)
Adjustments to reconcile net loss to net cash used for operating activities:	'	'	'
Depreciation and amortization	1,290,407	293,302	1,769,096
Stock-based compensation	1,788,734	863,127	3,255,373
Acquired in-process research and development	1,904,542	'	1,904,542
Increase (decrease) in cash resulting from changes in, net of acquisitions:	'	'	'
Grants and accounts receivable	116,755	-18,522	36,995
Prepaid expenses and other	-441,179	-76,947	-550,572
Accounts payable	878,641	-23,171	1,055,587
Accrued expenses and other liabilities	-116,251	10,043	108,428
Net cash used for operating activities	-16,489,614	-3,797,476	-25,282,113
Investing activities	'	'	'
Purchases of property and equipment	-420,233	-547,884	-2,141,950
Purchase of intangible assets	-511,065	'	-511,065
Cash acquired in connection with Mergers	427,818	'	532,678
Net cash used for investing activities	-503,480	-547,884	-2,120,337
Financing activities	'	'	'
Proceeds from issuance of common stock, net of issuance costs and repurchases	37,701,369	5,934,031	53,152,820
Proceeds from exercise of stock options	17,145	36,092	66,362
Net payments of deferred compensation	-1,000,000	'	-1,000,000
Net borrowings under debt agreements	6,850,000	'	6,850,000
Net cash provided by financing activities	43,568,514	5,970,123	59,069,182
Net change in cash and cash equivalents	26,575,420	1,624,763	31,666,732
Cash and cash equivalents at beginning of period	5,091,312	3,466,549	'
Cash and cash equivalents at end of period	31,666,732	5,091,312	31,666,732
Cash paid during the period for:	'	'	'
Income taxes	$800	$800	$5,600

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2013	Sep. 30, 2013	Oct. 31, 2013	Dec. 31, 2013
			Patents [Member]	IgDraSol, Inc. [Member]	Sherrington Pharmaceuticals, Inc. [Member]	Concortis Biosystems, Corp. [Member]
Non-cash investing, equipment purchase	$385,958	$237,960	'	'	'	'
Number of shares issued for purchase of patent rights	'	'	10,000	'	'	'
Value of common stock issued for purchase of patent rights	'	'	40,000	'	'	'
Issuance of common stock, shares	23,028,100	12,004,687	'	3,006,641	200,000	1,331,978
Issuance of common stock, value	$2,303	$1,200	'	$27,811,429	$1,697,600	$11,295,173

Nature_of_Operations_and_Busin

Nature of Operations and Business Activities	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Nature of Operations and Business Activities	'
	1. Nature of Operations and Business Activities
	Nature of Operations and Basis of Presentation
	Sorrento Therapeutics, Inc. (NASDAQ: SRNE), together with its wholly-owned subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the U.S., Europe and additional international markets. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including immunology and infectious diseases. The Company’s pipeline consists of its lead oncology product candidate Cynviloq™, a micellar paclitaxel formulation, resiniferatoxin (or RTX), a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease, as well as fully human therapeutic antibodies derived from our proprietary G-MAB® library platform and antibody drug conjugates, or ADCs, and recombinant intravenous immunoglobulin, or rIVIG.
	Through December 31, 2013, the Company had devoted substantially all of its efforts to product development, acquiring companies and in-licensing assets, raising capital and building infrastructure, and had not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
	The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries, IgDraSol, Inc., or IgDraSol, Sherrington Pharmaceuticals, Inc., or Sherrington, Concortis Biosystems, Corp., or Concortis, and Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong, which was registered effective December 4, 2012. Sorrento Hong Kong had no operating activity in 2012 and 2013. All intercompany balances and transactions have been eliminated in consolidation.
	Reverse Stock Split
	On July 30, 2013, the Company completed a 1-for-25 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action.
	Liquidity and Going Concern
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) conducts its bioequivalence, or BE, registration trial related to Cynviloq and prepares for its New Drug Application filing anticipated in 2015, (ii) advance RTX into clinical trials and potentially pursue other human or veterinary indications, (iii) continues to identify and advance a number of potential mAb and ADC drug candidates into preclinical and clinical development activities, (iv) continues development of, and seeks regulatory approvals for, its product candidates, and begin to commercialize any approved products, and (v) expand corporate infrastructure, including the costs associated with being a NASDAQ public company.
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. Contemporaneously with such closing, the Company repaid its then outstanding equipment loan balance of $762,361. In October 2013, the Company: (i) closed an underwritten public offering of 4,772,500 shares of its common stock, including the Underwriters exercise of an over-allotment of 622,500 shares of common stock, at $7.25 per share and total gross proceeds of $34.6 million, and (ii) issued an aggregate $1,850,000 principal amount of Convertible Promissory Notes (the “Notes”) with an interest rate of 7% per annum. Such Notes and related accrued interest automatically converted into 256,119 shares of common stock at $7.25 per share, effective in October 2013. In March 2014, the Company entered into an amended and restated loan and security agreement, increasing the September 2013 facility to $12,500,000 from $5,000,000, with the same two banks, which was funded at closing. This new loan will be used to pay off the Company’s existing $5,000,000 term loan. The interest rate on the amended and restated loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until October 1, 2014, after which equal monthly payments of principal and interest are due until the Term Loan maturity date of September 30, 2017. In the event the Company raises $30 million of net equity or proceeds from a collaboration, if any, the interest only period will be extended by six months. See Note 11. Management believes the Company has the ability to meet all obligations due over the course of the next twelve months.
	The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013. The Shelf Registration Statement provides the Company the ability to offer up to $100 million of securities, including equity and other securities as described in the registration statement. After the October 2013 underwritten offering, the Company has the ability to offer up to $65.4 million of additional securities. Pursuant to the Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
	Business Activities
	Reverse Merger Transaction and Accounting
	On September 21, 2009, QuikByte Software, Inc., a shell company (QuikByte) acquired Sorrento Therapeutics, Inc., a privately held Delaware corporation (STI), in a reverse merger (the “Reverse Merger”). Pursuant to the Reverse Merger, all of the issued and outstanding shares of STI common stock were exchanged into an aggregate of 6,775,032 shares of QuikByte common stock and STI became a wholly owned subsidiary of QuikByte. The holders of QuikByte’s common stock as of immediately prior to the Reverse Merger held an aggregate of 2,228,332 shares of QuikByte’s common stock. STI and QuikByte reincorporated in Delaware in December 2009, and on December 4, 2009, STI merged with and into QuikByte, the separate corporate existence of STI ceased and QuikByte continued as the surviving corporation. Contemporaneously, QuikByte Software, Inc. changed its name to Sorrento Therapeutics, Inc. In connection with the Reverse Merger, the Company received cash of $104,860.
	Agreement and Plan of Merger with IgDraSol
	On March 7, 2013, the Company entered into various agreements with IgDraSol, Inc. (“IgDraSol”) a private company focused on the development of Cynviloq, an oncologic agent for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers, as follows: (i) an exclusive option agreement, (ii) an asset purchase agreement pursuant to which the Company agreed to purchase all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol® and related technologies, and (iii) an initial services agreement, pursuant to which, IgDraSol is to provide certain product development and technology services related to the Company’s antibody platform. On September 9, 2013, the Company exercised its option to acquire IgDraSol. See Note 5.
	Loan and Security Agreement
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. In connection with such closing, the Company repaid its then outstanding equipment loan balance of $762,361. The interest rate on the term loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until November 1, 2014, after which equal monthly payments of principal and interest are due. The maturity date of the term loan is April 15, 2017 and is secured by a security interest in all of the Company’s assets except intellectual property. The Company’s intellectual property is subject to a negative pledge. In connection with the term loan, the lenders received a warrant to purchase an aggregate 31,250 shares of the Company’s common stock at an exercise price of $8.00 per share exercisable for seven years from the date of issuance. The value of the warrants, totaling $214,680, was recorded as debt discount and additional paid-in capital in the consolidated balance sheet as of December 31, 2013. See Note 6 and 11.
	Agreement and Plan of Merger with Sherrington Pharmaceuticals
	On October 9, 2013, the Company acquired Sherrington Pharmaceuticals, Inc. (“Sherrington”) a privately-held company focused on the development of a chronic pain treatment for end-stage cancer patients and other severe pain indications. The Company issued an aggregate of 200,000 shares of its common stock to the Sherrington shareholders. See Note 5.
	Underwritten Public Offering and Nasdaq Uplisting
	In October 2013, the Company closed an underwritten public offering of 4,150,000 shares, at $7.25 per share, and closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 622,500 shares of its common stock, with total gross proceeds of $34.6 million, before underwriting discounts and commissions and other offering expenses payable by the Company. The common stock began trading on The NASDAQ Capital Market on October 25, 2013 under the symbol “SRNE”.
	Agreement and Plan of Merger with Concortis
	On December 19, 2013, the Company completed its previously announced merger with Concortis Biosystems, Corp., (“Concortis”) providing the Company with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates (ADC’s) with site-specific toxin conjugation and consistent drug-antibody ratios. The Company issued 1,331,978 shares of its common stock to Concortis shareholders. See Note 5.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	2. Significant Accounting Policies
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of December 31, 2013 and 2012, the carrying amount of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
	Grants and Accounts Receivable
	Grants receivable at December 31, 2013 and 2012 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
	Accounts receivable at December 31, 2013 consists of trade receivables from sales and services provided to Concortis customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts.
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
	Acquisitions and Intangibles
	The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
	Patent rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of transfer of the rights to the Company in April 2013. The Company had no patent rights as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from inception (January 25, 2006) (“Inception”) through December 31, 2013 was $3,750, which has been included in intangibles amortization.
	License rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years from the date of acquisition of the rights in September 2013. The Company had no licenses rights as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from Inception through December 31, 2013 was $585,862, which has been included in intangibles amortization.
	Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of acquisition of the technology in December 2013. The Company had no acquired technology as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from Inception through December 31, 2013 was $5,779, which has been included in intangibles amortization.
	Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately five years from the date of acquisition. The Company had no customer relationships as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from Inception through December 31, 2013 was $8,679, which has been included in intangibles amortization.
	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through December 31, 2013.
	Research and Development Costs
	All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
	Acquired In-Process Research and Development Expense
	The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use.
	Income Taxes
	The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions.
	The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
	The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually.
	Revenue Recognition
	The Company’s inception to date revenues are generated primarily from three NIH and two U.S. Department of Treasury (or U.S. Treasury) grant awards and a feasibility study agreement, or the Collaboration Agreement, that the Company entered into with a third party in July 2010, and from revenues generated from Concortis. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
	The revenue from the Collaboration Agreement is derived from the completion of certain development services and the reimbursement of certain development costs incurred to provide such development services. Revenue from upfront, nonrefundable service fees are recognized when earned, as evidenced by written acknowledgement from the collaborator, or other persuasive evidence that all service deliverables have been achieved, provided that the service deliverables are substantive and their achievability was not reasonably assured at the inception of the Collaboration Agreement. Any amounts received prior to satisfying the Company’s revenue recognition criteria are recorded as deferred revenue.
	Revenues from sales and services are generated from the sale of customized reagents and providing professional services. Reagents are used for preparing ADCs, these reagents include industrial standard cytotoxins, linkers, and linker-toxins. The professional services include providing synthetic expertise to customer’s synthesis by delivering them proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured.
	The Company is obligated to accept from customers the return of products sold that are damaged or don’t meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
	Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
	The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at their estimated fair value as they vest.
	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments and unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended December 31, 2013 and 2012, the comprehensive loss was equal to the net loss.
	Net Loss per Share
	Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss per share includes the impact of potentially dilutive securities. During 2013 and 2012, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted net loss per share, as their effect would have been anti-dilutive.
	These outstanding securities consist of the following:
		Years Ended December 31,
		2013		2012
	Unvested Restricted Common stock subject to repurchase		—		13,458
	Outstanding options		1,047,300		419,600
	Outstanding warrants		221,850		8,000
	Weighted average exercise price of options	$	6.51	$	3.5
	Recent Accounting Pronouncements
	In February 2013, a new accounting standard was issued that amended existing guidance to improve the reporting of reclassifications out of accumulated other comprehensive income. The new standard requires the disclosure of significant amounts reclassified from each component of accumulated other comprehensive income and the income statement line items affected by the reclassification. The standard is effective prospectively for interim and annual periods beginning after December 15, 2012. We adopted this guidance as of January 1, 2013 and its adoption did not have an effect on our financial statements.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Property and Equipment	'
	3. Property and Equipment
	Property and equipment consisted of the following as of December 31, 2013 and 2012:
		December 31,
		2013			2012
	Furniture and fixtures	$	39,281		$	15,739
	Office equipment		80,764			23,039
	Lab equipment		3,186,735			1,855,220
	Leasehold improvements		65,679			65,679
			3,372,459			1,959,677
	Less accumulated depreciation and amortization		(932,606	)		(478,688	)
		$	2,439,853		$	1,480,989
	Depreciation expense for the years ended December 31, 2013 and 2012 and for the period from Inception through December 31, 2013 was $453,918, $293,302 and $932,607, respectively.

Significant_Agreements_and_Con

Significant Agreements and Contracts	12 Months Ended
	Dec. 31, 2013
Text Block [Abstract]	'
Significant Agreements and Contracts	'
	4. Significant Agreements and Contracts
	License Agreement with OPKO Health, Inc.
	In June 2009, the Company entered into a limited license agreement, or the OPKO License, with OPKO pursuant to which the Company granted OPKO an exclusive, royalty-free, worldwide license under all U.S. and foreign patents and patent applications owned or controlled by the Company or any of its affiliates, or the STI Patents, to (i) develop, manufacture, use, market, sell, offer to sell, import and export certain products related to the development, manufacture, marketing and sale of drugs for ophthalmological indications, or the OPKO Field, and (ii) use and screen any population of distinct molecules covered by any claim of the STI Patents or which is derived by use of any process or method covered by any claim of the STI Patents to identify, select and commercialize certain products within the OPKO Field. In December 2013, the Company entered into a termination and release agreement with OPKO whereby the Company terminated the OPKO License in its entirety for a cash payment of $2,680,000 which was recorded as in-process research and development expense.
	License Agreement with The Scripps Research Institute
	In January 2010, the Company entered into a license agreement, or the TSRI License, with The Scripps Research Institute, or TSRI. Under the TSRI License, TSRI granted the Company an exclusive, worldwide license to certain TSRI patent rights and materials based on quorum sensing for the prevention and treatment of Staphylococcus aureus (“Staph”) infections, including Methicillin-resistant Staph. In consideration for the license, the Company: (i) issued TSRI a warrant for the purchase of common stock, (ii) agreed to pay TSRI a certain annual royalty commencing in the first year after certain patent filing milestones are achieved, and (iii) agreed to pay a royalty on any sales of licensed products by the Company or its affiliates and a royalty for any revenues generated by the Company through its sublicense of patent rights and materials licensed from TSRI under the TSRI License. The TSRI License requires the Company to indemnify TSRI for certain breaches of the agreement and other matters customary for license agreements. The parties may terminate the TSRI License at any time by mutual agreement. In addition, the Company may terminate the TSRI License by giving 60 days notice to TSRI and TSRI may terminate the TSRI License immediately in the event of certain breaches of the agreement by the Company or upon the Company’s failure to undertake certain activities in furtherance of commercial development goals. Unless terminated earlier by either or both parties, the term of the TSRI License will continue until the final expiration of all claims covered by the patent rights licensed under the agreement. For the years ended December 31, 2013 and 2012 and for the period from Inception through December 31, 2013, the Company recorded $65,574, $41,835 and $192,919 in patent prosecution and maintenance costs associated with the TSRI License, respectively, which have been included in general and administrative expenses.
	The fair value of the warrants to purchase Company common stock, issued in connection with the TSRI License in 2010, of $17,989 was determined using the Black-Scholes valuation model with the following weighted-average assumptions: risk-free interest rate of 2.48%, no dividend yield, expected term of 10 years, and volatility of 102%. Such fair value has been included in general and administrative expenses for the period from Inception through December 31, 2013.
	License Agreement with B.G. Negev Technologies and Applications Ltd.
	In June 2013, the Company entered into an exclusive option agreement with B.G. Negev Technologies and Applications Ltd. (“BGN”). Pursuant to the terms of the option agreement, BGN granted the Company an option to receive an exclusive sub-licensable worldwide license in and to certain licensed patent rights to develop and commercialize the licensed products. Licensed patent rights refers to any rights arising out of or resulting from any patent application filed by the Company for certain BGN technology relating to a group of defined fully human antibodies that bind to a Hep. C protease enzyme. In exchange the Company agreed to file one provisional patent application and fund the research of the BGN technology. The option terminates on the latest of (i) twelve months from the effective date (June 30, 2013) or (ii) ten months from the date of filing of a first priority patent application as defined in the agreement.
	NIH Grants
	In May 2010, the NIAID awarded the Company an Advanced Technology Small Business Technology Transfer Research grant to support the Company’s program to generate and develop novel antibody therapeutics and vaccines to combat Staph infections, including Methicillin-resistant Staph, or the Staph Grant award. The project period for the Phase I Staph Grant award covered a two-year period which commenced in June 2010 and ended in May 2012, with a total grant award of $600,000. The Company recorded revenue associated with the grant as the related costs and expenses were incurred. During the year ended December 31, 2013 and 2012 and for the period from Inception through December 31, 2013, the Company recorded $0, $119,379 and $600,000 of revenue associated with the Staph Grant award, respectively.
	In July 2011, the NIAID awarded the Company a second Advanced Technology Small Business Technology Transfer Research grant to support the Company’s program to generate and develop antibody therapeutics and vaccines to combat C. difficile infections, or the C. difficile Grant award. The project period for the Phase I C. difficile Grant award covered a two-year period which commenced in June 2011 and ended in June 2013, with a total grant award of $600,000. During the years ended December 31, 2013 and 2012, and for the period from Inception through December 31, 2013, the Company recorded $143,940, $335,579 and $592,717 of revenue associated with the C. difficile Grant award, respectively.
	In June 2012, the NIAID awarded the Company a third Advanced Technology Small Business Technology Transfer Research grant to support the Company’s program to generate and develop novel human antibody therapeutics to combat Staph infections, including Methicillin-resistant Staph, or the Staph Grant II award. The project period for the phase I grant covers a two-year period which commenced in June 2012, with a total grant award of $600,000. During the years ended December 31, 2013 and 2012, and for the period from Inception through December 31, 2013, the Company recorded $307,833, $128,816 and $436,649 of revenue associated with the Staph Grant II award, respectively.
	Collaboration Agreement
	In July 2010, the Company entered into the Collaboration Agreement, with a third party. Under the terms of the Collaboration Agreement, the Company provided certain antibody screening services for an upfront cash fee of $200,000 and was reimbursed for certain costs and expenses associated with providing the services, or the Development Costs. The upfront fee and reimbursable Development Costs were accounted for as separate units of accounting. The Company recorded the gross amount of the reimbursable Development Costs as revenue and the costs associated with these reimbursements are reflected as a component of research and development expense.
	Any amounts received by the Company pursuant to the Collaboration Agreement prior to satisfying the Company’s revenue recognition criteria are recorded as deferred revenue. All agreed upon services under the Collaboration Agreement were delivered in March 2011. For the period from Inception through December 31, 2013, the Company recognized $223,453 in revenue.
	U.S. Treasury Grants
	During 2010, the U.S. Treasury awarded the Company two one-time grants totaling $394,480 for investments in qualifying therapeutic discovery projects under section 48D of the Internal Revenue Code. The grants cover reimbursement for qualifying expenses incurred by the Company in 2010 and 2009. For the period from Inception through December 31, 2013, the Company recognized $394,480 in grant revenue.

Mergers_and_Acquisitions

Mergers and Acquisitions	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
Mergers and Acquisitions	'
	5. Mergers and Acquisitions
	IgDraSol Acquisition Transactions
	On March 7, 2013, the Company entered into various agreements with IgDraSol as follows: (i) an exclusive option agreement whereby IgDraSol granted the Company an irrevocable option to acquire IgDraSol by means of an agreement and plan of merger, and was paid a non-refundable lump sum payment of $200,000 in April 2013, (ii) an asset purchase agreement pursuant to which the Company purchased all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol® and related technologies for a purchase price of $1,210,000, and (iii) an initial services agreement, pursuant to which IgDraSol provided the Company with certain product development and technology services related to our antibody platform for $1,000,000. All such services were completed prior to May 31, 2013. In April 2013, the Company entered into a development services agreement with IgDraSol related to the development of Tocosol and related technologies for a total of $1,721,193. Such services were completed in August 2013. The payment for the exclusive option agreement was capitalized and fully amortized as intangible amortization expense as of December 31, 2013.
	On September 9, 2013, the Company exercised its option to acquire IgDraSol whereby IgDraSol became a wholly-owned subsidiary and the Company acquired all rights to Cynviloq. Pursuant to the merger agreement, the Company issued 3,006,641 shares of common stock to IgDraSol stockholders and paid $382,275 in cash. Upon the later achievement of a specified regulatory milestone, the Company will issue an additional 1,306,272 shares of common stock to former IgDraSol stockholders.
	The Company’s lead compound is Cynviloq, a micellar paclitaxel formulation drug product. Cynviloq is currently approved and marketed in several countries, including South Korea for MBC and NSCLC under the trade name Genexol-PM®. The Company licensed exclusive distribution rights for Cynviloq in North America, the 27 countries of the European Union, and Australia, from Samyang Biopharmaceuticals Corporation, a South Korean corporation.
	The following table summarizes the purchase price of the IgDraSol acquisition, the identified assets acquired and liabilities assumed at the acquisition date ($ in thousands):
	Assets acquired:
	Cash	$	126
	Prepaid expenses & other		45
	PP&E		121
	Intangible license rights		29,105
	Goodwill		11,571
	Total assets		40,968
	Liabilities assumed:
	Accounts payable		168
	Accrued expenses		124
	Net deferred tax liability		11,571
	Total liabilities		11,863
	Total purchase price	$	29,105
	The intangible license rights will be amortized using the straight-line method through fiscal 2028 at an annual rate of $1,900,093.
	Sherrington Acquisition
	On October 9, 2013, the Company entered into an Agreement and Plan of Merger and Reorganization and acquired privately-held Sherrington in exchange for 200,000 shares of its common stock, for an aggregate purchase price of $1,697,600. Sherrington is focused on the development of a treatment for intractable pain in end-stage disease. RTX is a novel, non-opiate, small molecule that permanently eliminates pain experienced by end-stage cancer patients when directly interacting with the nerve cells. RTX is currently being tested in an investigator-sponsored Phase I/II clinical trial under a Cooperative Research and Development Agreement. To date, 10 patients with terminal cancer pain have been treated at the NIH. The Company intends to launch additional trials to rapidly advance clinical development of the drug in patients with terminal cancer pain. The purchase price was recognized as acquired in-process research and development expense.
	Concortis Acquisition
	On December 19, 2013, the Company completed its Agreement and Plan of Merger and acquired privately-held Concortis. Upon closing, the Company issued an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. Certain Concortis employees and consultants are to receive annual deferred compensation payments totaling $1,000,000 on December 31 of each of the years ending 2013, 2014, 2015, and 2016. The net present value of the deferred compensation payments was calculated using the effective interest method, and is included in the purchase price. The total transaction is valued at $14.7 million. Concortis, now a wholly-owned subsidiary, has proprietary cytotoxic payloads as well as C-lock® and K-lock® conjugation technologies that allow for site-specific toxin conjugation to the antibody. These next generation technologies may improve the overall stability and potency of the ADCs. First-generation conjugation technologies lead to inconsistent drug-antibody ratios, which result in a heterogeneous mixture of ADCs. This variability has been a constraining factor in unlocking the full therapeutic potential for current-generation ADCs. The ADC technology complements the Company’s existing development programs, particularly its G-MAB® antibody library and related monoclonal antibodies. Concortis uses its proprietary technologies to provide various customized reagents as well as drug conjugation services to customers in the pharmaceutical industry.
	The following table summarizes the purchase price of the Concortis acquisition, the identified assets acquired and liabilities assumed at the acquisition date ($ in thousands):
	Assets acquired:
	Cash	$	302
	A/R, prepaid expenses & other		535
	PP&E		441
	Customer relationships		1,320
	Technologies		3,410
	Goodwill		11,798
	Total assets		17,806
	Liabilities assumed:
	Accounts payable and accrued expenses		1,118
	Net deferred tax liability		2,005
	Total liabilities		3,123
	Total estimated purchase price	$	14,683
	The intangible customer relationships and acquired technology will be amortized using the straight-line method through fiscal 2018 and 2033, at an annual rate of $264,000 and $175,773, respectively.
	The IgDraSol, Sherrington and Concortis acquisitions are being accounted for in accordance with the acquisition method of accounting under FASB ASC Topic 805, “Business Combinations” (“Topic 805”). Topic 805 requires, among other things, that identifiable assets acquired and liabilities assumed be recognized at their fair values as of the Acquisition Date. Under the acquisition method of accounting, the purchase consideration is allocated to the assets acquired, including tangible assets and other identifiable intangible assets and liabilities assumed, based on their estimated fair market values on the date of acquisition. Any excess purchase price after the initial allocation to identifiable net tangible and identifiable intangible assets is assigned to goodwill. The fair values set forth above are based in part on third party appraisals in accordance with Topic 805.
	Each of these acquisitions are being treated for tax purposes as nontaxable transactions and as such, the historical tax bases of the acquired assets and assumed liabilities, net operating losses, and other tax attributes of IgDraSol, Sherrington and Concortis will carryover. As a result, no new tax goodwill will be created in connection with these acquisitions as there is no step-up to fair value of the underlying tax bases of the acquired net assets. Acquisition accounting includes the establishment of a net deferred tax asset or liability resulting from book tax basis differences related to assets acquired and liabilities assumed on the date of acquisition. Acquisition date deferred tax liabilities relate to specifically identified non-goodwill intangibles acquired. The estimated net deferred tax liability was determined as follows ($ in thousands):
		IgDraSol			Sherrington			Concortis			Total
	Intangible license rights acquired	$	29,105		$	—		$	—		$	29,105
	Acquired in-process research and development					1,904						1,904
	Intangible customer relationships acquired		—			—			1,320			1,320
	Intangible technologies acquired		—			—			3,410			3,410
	Book basis		29,105			1,904			4,730			35,739
	Tax basis		55			218			(303	)		(30	)
	Difference		(29,050	)		(1,686	)		(5,033	)		(35,769	)
	Estimated tax rate		39.83	%		39.83	%		39.83	%		39.83	%
	Estimated net deferred tax liability	$	(11,571	)	$	(672	)	$	(2,005	)	$	(14,248	)
	Unaudited Pro Forma Financial Information
	The unaudited pro forma financial information in the table below summarizes the combined results of operations for the Company as though the IgDraSol, Sherrington and Concortis acquisitions occurred as of January 1, 2013. The unaudited pro forma financial information for all periods presented also includes the business combination accounting effects resulting from these acquisitions including amortization charges from acquired intangible assets. The unaudited pro forma financial information as presented below is for informational purposes only and does not purport to be indicative of the results of operations for future periods or the results what actually would have been realized had the entities been a single entity during these periods. The unaudited pro forma combined results are presented in thousands, except share and per share information.
		Years Ended December 31,
		2013			2012
	Total Revenues	$	3,850		$	584
	Loss from operations	$	(23,589	)	$	(4,853	)
	Net loss	$	(24,084	)	$	(4,845	)
	Net loss per share—basic and diluted	$	(1.60	)	$	(0.42	)

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Debt	'
	6. Debt
	Equipment Loan and Security Agreement
	In February 2013, the Company entered into an equipment loan and security agreement with a bank pursuant to which the lender provided the Company a loan in the principal amount of $875,888 to finance certain equipment. Interest accrues on the outstanding advance at the fixed rate of 5.15%. The Company granted the lender a security interest in any equipment financed under the equipment loan agreement. In September 2013, the equipment loan was paid in full, the Company had no further obligations thereunder, and the bank released its security interest in such assets.
	Loan and Security Agreement
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. The interest rate on such loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until November 1, 2014, after which equal monthly payments of principal and interest are due until the loan maturity date of April 15, 2017. The loan is secured by a security interest in all of the Company’s assets except intellectual property, which is subject to a negative pledge. In connection with the loan, the Lenders received a warrant to purchase an aggregate 31,250 shares of the Company’s common stock at an exercise price of $8.00 per share exercisable for seven years from the date of issuance. The original value of the warrants, totaling $214,680, was recorded as debt discount and additional paid-in capital. See Note 11.
	At the Company’s option, it may prepay all of the outstanding principal balance, subject to certain pre-payment fees ranging from 1% to 3% of the prepayment amount. In the event of a final payment of the loans under the loan agreement, either in the event of repayment of the loan at maturity or upon any prepayment, the Company is obligated to pay the amortized portion of the final fee of $200,000.
	The Company is also subject to certain affirmative and negative covenants under the loan agreement, including limitations on its ability to: undergo certain change of control events; convey, sell, lease, license, transfer or otherwise dispose of any equipment financed by loans under the loan agreement; create, incur, assume, guarantee or be liable with respect to indebtedness, subject to certain exceptions; grant liens on any equipment financed under the loan agreement; and make or permit any payment on specified subordinated debt. In addition, under the loan agreement, subject to certain exceptions, the Company is required to maintain with the lender its primary operating, other deposit and securities accounts.
	Long-term debt and unamortized discount balances are as follows:
	Balance at December 31, 2012	$	—
	Face value of term loan		5,000,000
	Fair value of warrants		(214,680	)
	Accretion of debt discount		19,474
	Balance at December 31, 2013	$	4,804,794
	Future minimum payments under the loan and security agreement are as follows:
	Year Ending December 31,
	2014	$	851,106
	2015		2,211,925
	2016		2,211,925
	2017		734,841
	Total future minimum payments		6,009,797
	Unamortized interest		(1,009,797	)
	Debt discount		(195,206	)
	Total minimum payment		4,804,794
	Current portion		(373,930	)
	Long-term debt	$	4,430,864

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Stockholders' Equity	'
	7. Stockholders’ Equity
	Common Stock and Related Party Transaction
	In February 2006, in conjunction with the founding of the Company, 4,077,493 shares of common stock were issued to founders, at the pre-Merger par value, for total consideration of $400 in cash.
	In March 2009, the Company: (i) issued 296,155 shares of restricted common stock to certain consultants, at the pre-Merger par value, for aggregate gross proceeds of $291, and (ii) issued 40,775 shares of unrestricted common stock to certain consultants for aggregate cash gross proceeds of $10 and issued a note receivable for $30. The note was paid in full in 2010.
	In June 2009, the Company issued 2,360,611 shares of common stock at $0.98 per share for aggregate gross proceeds of $2,300,000 in a private placement transaction. Related stock issuance costs totaled $25,999.
	In September 2009, and in connection with the Merger, the Company: (i) issued 1,785,375 shares of common stock, in a private placement transaction, at $1.12 per share for aggregate gross proceeds of $1,999,620, (ii) issued 442,958 shares of common stock to the former stockholders of QuikByte, and (iii) incurred costs associated with the Merger totaling $168,767.
	In December 2010, the Company issued 1,028,686 shares of common stock, in a private placement transaction, at $3.50 per share for aggregate gross proceeds of $3.6 million. Related stock issuance costs were estimated at $159,905. In 2011, the Company reduced its stock issuance costs accrued in 2010 by $80,039.
	In December 2011, the Company entered into a Stock Purchase Agreement and issued 500,000 shares of common stock, in a private placement transaction, at $4.00 per share for aggregate gross proceeds of $2,000,000. In May 2012, pursuant to the Stock Purchase Agreement, as amended and restated, the Company issued 1,500,000 shares of common stock, in a private placement transaction, at $4.00 per share for aggregate gross proceeds of $6,000,000. Two hundred and fifty thousand of the shares were purchased by an investor, Hongye SD Group, LLC, of which Dr. Henry Ji, the Company’s Chief Executive Officer and President, is a managing director.
	In January 2013, the Company entered into the assignment agreement and issued 10,000 shares of common stock valued at $40,000.
	In March 2013, the Company entered into a Stock Purchase Agreement and issued 1,426,406 shares of common stock, in a private placement transaction, at $4.50 per share for aggregate gross proceeds of $6,418,495.
	On October 30, 2013, the Company closed an underwritten public offering of 4,150,000 shares of common stock, at $7.25 per share, and closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 622,500 shares of its common stock, with total gross proceeds of $34.6 million, before underwriting discounts and commissions and other offering expenses payable by the Company. The common stock began trading on The NASDAQ Capital Market on October 25, 2013 under the symbol “SRNE”.
	Purchase Warrants
	Concurrent with the offering, the Company agreed to issue and sell to the underwriters a warrant (“Underwriters Warrant”) for the purchase of an aggregate of 182,600 shares of common stock, for $100. The Underwriters Warrant agreement is exercisable, in whole or in part, commencing on a date which is one (1) year after the effective date of the Registration Statement and expiring on the five-year anniversary of the effective date of the Registration Statement at an initial exercise price per share of common stock of $9.0625, which is equal to 125% of the initial public offering price of $7.25 per share.
	Convertible Promissory Notes
	In October 2013, the Company issued an aggregate $1,850,000 principal amount of Notes that bear interest at 7% per annum. Concurrently with the closing of the public offering, such Notes and related accrued interest totaling $6,832 automatically converted into 256,119 shares of common stock.
	Stock Incentive Plans
	2009 Equity Incentive Plan
	In February 2009, prior to the Merger, the Company’s Board of Directors approved the 2009 Equity Incentive Plan, or the EIP, under which 400,000 shares of common stock were reserved for issuance to employees, non-employee directors and consultants of the Company. In March 2009, the Company issued 296,154 restricted common stock awards to certain consultants for aggregate gross proceeds of $291, of which the Company repurchased 44,166 unvested shares of restricted common stock for $43 in January 2011. The restricted shares vest monthly over four years and all remaining shares were fully vested as of December 31, 2013. No further shares are available for grant under the EIP.
	2009 Non-Employee Director Grants
	In September 2009, prior to the adoption of the 2009 Stock Incentive Plan, the Company’s Board of Directors approved the reservation and issuance of 8,000 nonstatutory stock options to the Company’s non-employee directors. The outstanding options vested on the one year anniversary of the vesting commencement date in October 2010. Such options are exercisable on the two year anniversary of the grant date and are generally exercisable for up to 10 years from the grant date. No further shares may be granted under this plan and, as of December 31, 2013, 3,200 options were outstanding.
	The following table summarizes stock option activity as of December 31, 2012 and 2013, and the changes for the years then ended:
		Options			Weighted-
		Outstanding			Average
					Exercise Price
	Outstanding at December 31, 2011		4,800		$	1.12
	Options Granted		—			—
	Options Canceled		—			—
	Options Exercised		(1,600	)	$	1.12
	Outstanding at December 31, 2012		3,200		$	1.12
	Options Granted		—			—
	Options Canceled		—			—
	Options Exercised		—			—
	Outstanding, Vested and Exercisable at December 31, 2013		3,200		$	1.12
	2009 Stock Incentive Plan
	In October 2009, the Company’s stockholders approved the 2009 Stock Incentive Plan. In April 2013, the Company’s stockholders approved, among other items, the amendment and restatement of the 2009 Stock Incentive Plan, or the Stock Plan, to increase the number of common stock authorized to be issued pursuant to the Stock Plan to 1,360,000. Such shares of the Company’s common stock are reserved for issuance to employees, non-employee directors and consultants of the Company. In addition, this amount will be automatically increased annually on the first day of each fiscal year by the lesser of: (i) 1% of the aggregate number of shares of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year, (ii) 200,000 shares, or (iii) an amount approved by the administrator of the Stock Plan. The Stock Plan provides for the grant of incentive stock options, non-incentive stock options, stock appreciation rights, restricted stock awards, unrestricted stock awards, restricted stock unit awards and performance awards to eligible recipients. Recipients of stock options shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant. The maximum term of options granted under the Stock Plan is ten years. Employee option grants will generally vest 25% on each anniversary of the original vesting date over four years. The vesting schedules for grants to non-employee directors and consultants will be determined by the Company’s Compensation Committee. Stock options are generally not exercisable prior to the applicable vesting date, unless otherwise accelerated under the terms of the applicable stock plan agreement. Unvested shares of the Company’s common stock issued in connection with an early exercise however, may be repurchased by the Company upon termination of the optionee’s service with the Company.
	The following table summarizes stock option activity as of December 31, 2012 and 2013, and the changes for the years then ended:
		Options			Weighted-			Aggregate Intrinsic
		Outstanding			Average			Value
					Exercise Price
	Outstanding at December 31, 2011		113,100		$	3
	Options Granted		341,400		$	4
	Options Canceled		(28,900	)	$	3.75
	Options Exercised		(9,200	)	$	3.25
	Outstanding at December 31, 2012		416,400		$	3.75		$	54,750
	Options Granted		650,200		$	8.19
	Options Canceled		(15,200	)	$	3.92
	Options Exercised		(7,300	)	$	2.35
	Outstanding at December 31, 2013		1,044,100		$	6.52		$	1,859,880
	Vested and Exercisable at December 31, 2013		319,325		$	5.8		$	777,462
	The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of employee stock options was estimated at the grant date using the following assumptions:
		Years Ended December 31,
		2013			2012
	Weighted-average grant date fair value	$	8.19		$	7.25
	Dividend yield		—			—
	Volatility		87	%		103	%
	Risk-free interest rate		1.68	%		0.88	%
	Expected life of options		6.1 years			5.5 years
	The assumed dividend yield was based on the Company’s expectation of not paying dividends in the foreseeable future. Due to the Company’s limited historical data, the estimated volatility incorporates the historical and implied volatility of comparable companies whose share prices are publicly available. The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The weighted average expected life of options was estimated using the average of the contractual term and the weighted average vesting term of the options.
	The total employee stock-based compensation recorded as operating expenses was $1,545,038, $324,958, and $1,963,854 for the years ended December 31, 2013 and 2012 and for the period from Inception through December 31, 2013, respectively.
	The total unrecognized compensation cost related to unvested stock option grants as of December 31, 2013 was $3,752,673 and the weighted average period over which these grants are expected to vest is 3.3 years.
	The Company records equity instruments issued to non-employees as expense at their fair value over the related service period as determined in accordance with the authoritative guidance and periodically revalues the equity instruments as they vest. Stock-based compensation expense related to non-employee consultants recorded as operating expenses was $243,696, $538,169, and $1,291,519 for the years ended December 31, 2013 and 2012 and for the period from Inception through December 31, 2013, respectively.
	Common Stock Reserved for Future Issuance
	Common stock reserved for future issuance consists of the following at December 31, 2013:
Common stock warrants outstanding under the TSRI License		8,000
Common stock warrants outstanding under the Underwriters Agreement		182,600
Common stock warrants outstanding under the loan and security agreement		31,250
Common stock options outstanding under the EIP		3,200
Authorized for future grant or issuance under the Stock Plan		293,400
Issuable to former IgDraSol stockholders upon achievement of specified regulatory milestone		1,306,272
Issuable under assignment agreement based upon achievement of certain milestones		80,000
		1,904,722

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	8. Commitments and Contingencies
	Litigation
	In the normal course of business, the Company may be named as a defendant in one or more lawsuits. Management is currently not aware of any pending lawsuits.
	Operating Leases
	The Company currently leases: (i) approximately 12,000 square feet of corporate office and laboratory space in San Diego, California, (ii) approximately 6,350 square feet of laboratory and office space at a second location in San Diego, California, and (iii) approximately 2,400 square feet of office space in Irvine, California. Our initial lease agreement for our corporate office and laboratory space expires in September 2014, but includes an option to extend the term of the lease for one additional four-year period. In June 2012, we entered into a separate lease arrangement for an additional 3,216 square feet of laboratory space adjacent to our corporate office, which expires in April 2017, and contains an option to extend the term for the additional rental space by five years at the then prevailing rate. The lease for our second location in San Diego expires in June 2018. Our Irvine lease, as amended, expires in March 2015. We believe that our current facilities are adequate to meet our needs for the foreseeable future and that, should it be needed, suitable additional space will be available to accommodate expansion of our operations on commercially reasonable terms.
	For all leased properties the Company has provided a total security deposit of $50,479 to secure its obligations under the various leases, which has been included in prepaid and other assets.
	Minimum future non-cancelable annual operating lease obligations are as follows for the years ending December 31:
	2014	$	341,325
	2015		214,427
	2016		202,272
	2017		186,786
	2018		89,520
		$	1,034,330
	Rental expense paid for the years ended December 31, 2013 and 2012 and for the period from Inception through December 31, 2013 under the above leases totaled $198,259, $128,300 and $533,443, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	9. Income Taxes
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets are as follows as of December 31, 2013 and 2012:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards and credits	$	11,995,000		$	5,047,000
	Stock based compensation		506,000			97,000
	Accrued expenses and other		(202,000	)		(99,000	)
	Total deferred tax assets		12,299,000			5,045,000
	Less valuation allowance		(13,930,000	)		(5,045,000	)
	Net deferred tax assets		(1,631,000	)		—
	Deferred tax liabilities:
	Amortization of intangibles		(12,617,000	)		—
	Net deferred tax liabilities	$	(14,248,000	)	$	—
	The Company has evaluated the available evidence supporting the realization of its gross deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that the deferred tax assets will not be realized. Due to such uncertainties surrounding the realization of the domestic deferred tax assets, the Company maintains a valuation allowance of $13,930,000 against its deferred tax assets as of December 31, 2013. Realization of the deferred tax assets will be primarily dependent upon the Company’s ability to generate sufficient taxable income prior to the expiration of its net operating losses.
	As of December 31 2013, the Company had net operating loss carryforwards of approximately $28,138,000 and $25,732,000 for federal and state income tax purposes, respectively. These may be used to offset future taxable income and will begin to expire in varying amounts in 2027 to 2033. The Company also has research and development credits of approximately $541,000 and $586,000 for federal and state income tax purposes, respectively. The federal credits may be used to offset future taxable income and will begin to expire in varying amounts in 2029 to 2033. The state credits may be used to offset future taxable income, such credits carryforward indefinitely.
	The Company is subject to taxation in the U.S. and California jurisdictions. Currently, no historical years are under examination. The Company’s tax years ending December 31, 2013 and 2012 are subject to examination by the U.S. and state taxing authorities due to the carryforward of unutilized net operating losses and research and development credits.
	Utilization of the Company’s net operating loss carryforwards and research and development credit carryforwards may be subject to a substantial annual limitation due to an “ownership change” that may have occurred, or that could occur in the future, as defined and required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state provisions. These ownership changes may limit the amount of net operating loss carryforwards and research and development credit carryforwards, and other tax attributes that can be utilized annually to offset future taxable income and tax, respectively. Any limitation may result in the expiration of a portion of the net operating loss carryforwards or research and development credit carryforwards before utilization.
	In general, an “ownership change” results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50% of the outstanding stock of a company by certain stockholders or public groups. The Company intends to complete a study in the future to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company’s formation, and will complete such study before the use of any of the aforementioned attributes.

401k_Plans

401(k) Plans	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
401(k) Plans	'
	10. 401(k) Plans
	The Company maintains a defined contribution 401(k) plan available to eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company, at its discretion, may make certain contributions to the 401(k) plan. Through December 31, 2013, no such contributions were made. In addition, Concortis maintains a defined contribution 401(k) plan available to its eligible employees. Employee contributions are voluntary and are determined on an individual basis, limited to the maximum amount allowable under federal tax regulations. The Company may make matching contributions to the Concortis 401(k) plan, in its sole discretion.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events	'
	11. Subsequent Events
	On March 25, 2014, the Company announced the formation of a wholly-owned subsidiary, Ark Animal Therapeutics, Inc., or Ark, which will initially focus on developing animal health applications for RTX. RTX targets TRPV-1, a receptor expressed on afferent nerves that has been shown to become hyper-activated in diseases associated with chronic inflammation and the resulting severe pain. The Company intends to assemble a seasoned management team to operate and secure external financing for Ark’s planned development activities.
	In March 2014, the Company entered into an amended and restated loan and security agreement, increasing the September 2013 facility to $12,500,000 from $5,000,000, with the same two banks. Such loan was funded at closing and is secured by a lien covering substantially all of the Company’s assets, excluding intellectual property, which is subject to a negative pledge. As amended and restated, the loan interest rate is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until October 1, 2014, after which equal monthly payments of principal and interest are due until the loan maturity date of September 30, 2017. In the event the Company raises $30 million of net equity or proceeds from a collaboration, if any, the interest only period will be extended by six months. The amended and restated loan: (i) interest rate is 7.95% per annum, and (ii) provided the Lenders warrants to purchase an aggregate of 34,642 shares of the Company’s common stock at an exercise price of $12.99 per share exercisable for seven years from the date of issuance.
	On March 30, 2014, Dr. Daniel Levitt resigned as a member of our board of directors. On March 31, 2014, Richard Vincent, Executive Vice President and Chief Financial Officer resigned as a member of our board of directors so that we would remain in compliance with Nasdaq rules with respect to number of independent directors.

Nature_of_Operations_and_Busin1

Nature of Operations and Business Activities (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Nature of Operations and Basis of Presentation	'
	Nature of Operations and Basis of Presentation
	Sorrento Therapeutics, Inc. (NASDAQ: SRNE), together with its wholly-owned subsidiaries (collectively, the “Company”) is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs in the U.S., Europe and additional international markets. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain, but is also developing therapeutic products for other indications, including immunology and infectious diseases. The Company’s pipeline consists of its lead oncology product candidate Cynviloq™, a micellar paclitaxel formulation, resiniferatoxin (or RTX), a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease, as well as fully human therapeutic antibodies derived from our proprietary G-MAB® library platform and antibody drug conjugates, or ADCs, and recombinant intravenous immunoglobulin, or rIVIG.
	Through December 31, 2013, the Company had devoted substantially all of its efforts to product development, acquiring companies and in-licensing assets, raising capital and building infrastructure, and had not realized revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.
	The accompanying consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries, IgDraSol, Inc., or IgDraSol, Sherrington Pharmaceuticals, Inc., or Sherrington, Concortis Biosystems, Corp., or Concortis, and Sorrento Therapeutics, Inc. Hong Kong Limited, or Sorrento Hong Kong, which was registered effective December 4, 2012. Sorrento Hong Kong had no operating activity in 2012 and 2013. All intercompany balances and transactions have been eliminated in consolidation.
Reverse Stock Split	'
	Reverse Stock Split
	On July 30, 2013, the Company completed a 1-for-25 reverse split of its common stock. All common shares and per common share amounts in the financial statements and footnotes have been adjusted retroactively to reflect the effects of this action.
Liquidity and Going Concern	'
	Liquidity and Going Concern
	The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) conducts its bioequivalence, or BE, registration trial related to Cynviloq and prepares for its New Drug Application filing anticipated in 2015, (ii) advance RTX into clinical trials and potentially pursue other human or veterinary indications, (iii) continues to identify and advance a number of potential mAb and ADC drug candidates into preclinical and clinical development activities, (iv) continues development of, and seeks regulatory approvals for, its product candidates, and begin to commercialize any approved products, and (v) expand corporate infrastructure, including the costs associated with being a NASDAQ public company.
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. Contemporaneously with such closing, the Company repaid its then outstanding equipment loan balance of $762,361. In October 2013, the Company: (i) closed an underwritten public offering of 4,772,500 shares of its common stock, including the Underwriters exercise of an over-allotment of 622,500 shares of common stock, at $7.25 per share and total gross proceeds of $34.6 million, and (ii) issued an aggregate $1,850,000 principal amount of Convertible Promissory Notes (the “Notes”) with an interest rate of 7% per annum. Such Notes and related accrued interest automatically converted into 256,119 shares of common stock at $7.25 per share, effective in October 2013. In March 2014, the Company entered into an amended and restated loan and security agreement, increasing the September 2013 facility to $12,500,000 from $5,000,000, with the same two banks, which was funded at closing. This new loan will be used to pay off the Company’s existing $5,000,000 term loan. The interest rate on the amended and restated loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until October 1, 2014, after which equal monthly payments of principal and interest are due until the Term Loan maturity date of September 30, 2017. In the event the Company raises $30 million of net equity or proceeds from a collaboration, if any, the interest only period will be extended by six months. See Note 11. Management believes the Company has the ability to meet all obligations due over the course of the next twelve months.
	The Company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, strategic collaborations, licensing arrangements, asset sales, government grants or other arrangements. The Company filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”), which was declared effective by the SEC in July 2013. The Shelf Registration Statement provides the Company the ability to offer up to $100 million of securities, including equity and other securities as described in the registration statement. After the October 2013 underwritten offering, the Company has the ability to offer up to $65.4 million of additional securities. Pursuant to the Shelf Registration Statement, the Company may offer such securities from time to time and through one or more methods of distribution, subject to market conditions and the Company’s capital needs. Specific terms and prices will be determined at the time of each offering under a separate prospectus supplement, which will be filed with the SEC at the time of any offering. However, the Company cannot be sure that such additional funds will be available on reasonable terms, or at all. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. In addition, if the Company does not meet its payment obligations to third parties as they come due, it may be subject to litigation claims. Even if the Company is successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
	If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result. If the Company raises additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict the Company’s ability to operate its business.
Business Activities	'
	Business Activities
	Reverse Merger Transaction and Accounting
	On September 21, 2009, QuikByte Software, Inc., a shell company (QuikByte) acquired Sorrento Therapeutics, Inc., a privately held Delaware corporation (STI), in a reverse merger (the “Reverse Merger”). Pursuant to the Reverse Merger, all of the issued and outstanding shares of STI common stock were exchanged into an aggregate of 6,775,032 shares of QuikByte common stock and STI became a wholly owned subsidiary of QuikByte. The holders of QuikByte’s common stock as of immediately prior to the Reverse Merger held an aggregate of 2,228,332 shares of QuikByte’s common stock. STI and QuikByte reincorporated in Delaware in December 2009, and on December 4, 2009, STI merged with and into QuikByte, the separate corporate existence of STI ceased and QuikByte continued as the surviving corporation. Contemporaneously, QuikByte Software, Inc. changed its name to Sorrento Therapeutics, Inc. In connection with the Reverse Merger, the Company received cash of $104,860.
	Agreement and Plan of Merger with IgDraSol
	On March 7, 2013, the Company entered into various agreements with IgDraSol, Inc. (“IgDraSol”) a private company focused on the development of Cynviloq, an oncologic agent for the treatment of metastatic breast cancer, or MBC, non-small cell lung cancer, or NSCLC, and other cancers, as follows: (i) an exclusive option agreement, (ii) an asset purchase agreement pursuant to which the Company agreed to purchase all documentation, equipment, information and other know-how related to micellar nanoparticle technology encompassing Tocosol® and related technologies, and (iii) an initial services agreement, pursuant to which, IgDraSol is to provide certain product development and technology services related to the Company’s antibody platform. On September 9, 2013, the Company exercised its option to acquire IgDraSol. See Note 5.
	Loan and Security Agreement
	In September 2013, the Company entered into a $5,000,000 loan and security agreement with two banks pursuant to which the lenders provided the Company a term loan, which was funded at closing. In connection with such closing, the Company repaid its then outstanding equipment loan balance of $762,361. The interest rate on the term loan is 7.95% per annum. The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until November 1, 2014, after which equal monthly payments of principal and interest are due. The maturity date of the term loan is April 15, 2017 and is secured by a security interest in all of the Company’s assets except intellectual property. The Company’s intellectual property is subject to a negative pledge. In connection with the term loan, the lenders received a warrant to purchase an aggregate 31,250 shares of the Company’s common stock at an exercise price of $8.00 per share exercisable for seven years from the date of issuance. The value of the warrants, totaling $214,680, was recorded as debt discount and additional paid-in capital in the consolidated balance sheet as of December 31, 2013. See Note 6 and 11.
	Agreement and Plan of Merger with Sherrington Pharmaceuticals
	On October 9, 2013, the Company acquired Sherrington Pharmaceuticals, Inc. (“Sherrington”) a privately-held company focused on the development of a chronic pain treatment for end-stage cancer patients and other severe pain indications. The Company issued an aggregate of 200,000 shares of its common stock to the Sherrington shareholders. See Note 5.
	Underwritten Public Offering and Nasdaq Uplisting
	In October 2013, the Company closed an underwritten public offering of 4,150,000 shares, at $7.25 per share, and closed the full exercise of the over-allotment option granted to the representative of the underwriters to purchase an additional 622,500 shares of its common stock, with total gross proceeds of $34.6 million, before underwriting discounts and commissions and other offering expenses payable by the Company. The common stock began trading on The NASDAQ Capital Market on October 25, 2013 under the symbol “SRNE”.
	Agreement and Plan of Merger with Concortis
	On December 19, 2013, the Company completed its previously announced merger with Concortis Biosystems, Corp., (“Concortis”) providing the Company with a comprehensive technology platform to create a new generation of homogenous antibody drug conjugates (ADC’s) with site-specific toxin conjugation and consistent drug-antibody ratios. The Company issued 1,331,978 shares of its common stock to Concortis shareholders. See Note 5.
Use of Estimates	'
	Use of Estimates
	The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. The Company minimizes its credit risk associated with cash and cash equivalents by periodically evaluating the credit quality of its primary financial institution. The balance at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	The Company’s financial instruments consist of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. As of December 31, 2013 and 2012, the carrying amount of cash and cash equivalents, grants and accounts receivable, prepaid expenses and other assets, accounts payable and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.
Grants and Accounts Receivable	'
	Grants and Accounts Receivable
	Grants receivable at December 31, 2013 and 2012 represent amounts due under several federal contracts with the National Institute of Allergy and Infectious Diseases, or NIAID, a division of the National Institutes of Health, or NIH, collectively, the NIH Grants. The Company considers the grants receivable to be fully collectible; accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.
	Accounts receivable at December 31, 2013 consists of trade receivables from sales and services provided to Concortis customers, which are generally unsecured and due within 30 days. Estimated credit losses related to trade accounts receivable are recorded as general and administrative expenses and as an allowance for doubtful accounts within grants and accounts receivable, net. The Company reviews reserves and makes adjustments based on historical experience and known collectability issues and disputes. When internal collection efforts on accounts have been exhausted, the accounts are written off by reducing the allowance for doubtful accounts.
Property and Equipment	'
	Property and Equipment
	Property and equipment are carried at cost less accumulated depreciation. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the assets, which are generally three to five years. Leasehold improvements are amortized over the lesser of the life of the lease or the life of the asset. Repairs and maintenance are charged to expense as incurred.
Acquisitions and Intangibles	'
	Acquisitions and Intangibles
	The Company has engaged in business combination activity. The accounting for business combinations requires management to make judgments and estimates of the fair value of assets acquired, including the identification and valuation of intangible assets, as well as liabilities assumed. Such judgments and estimates directly impact the amount of goodwill recognized in connection with each acquisition, as goodwill presents the excess of the purchase price of an acquired business over the fair value of its net tangible and identifiable intangible assets.
	Patent rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of transfer of the rights to the Company in April 2013. The Company had no patent rights as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from inception (January 25, 2006) (“Inception”) through December 31, 2013 was $3,750, which has been included in intangibles amortization.
	License rights are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately fifteen years from the date of acquisition of the rights in September 2013. The Company had no licenses rights as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from Inception through December 31, 2013 was $585,862, which has been included in intangibles amortization.
	Acquired technology is stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately nineteen years from the date of acquisition of the technology in December 2013. The Company had no acquired technology as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from Inception through December 31, 2013 was $5,779, which has been included in intangibles amortization.
	Customer relationships are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the assets, determined to be approximately five years from the date of acquisition. The Company had no customer relationships as of December 31, 2012. Amortization expense for the year ended December 31, 2013 and for the period from Inception through December 31, 2013 was $8,679, which has been included in intangibles amortization.
Impairment of Long-Lived Assets	'
	Impairment of Long-Lived Assets
	The Company evaluates its long-lived assets with definite lives, such as property and equipment, acquired technology, customer relationships, patent and license rights, for impairment by considering competition by products prescribed for the same indication, the likelihood and estimated future entry of non-generic and generic competition with the same or similar indication and other related factors. The factors that drive the estimate of the life are often uncertain and are reviewed on a periodic basis or when events occur that warrant review. Recoverability is measured by comparison of the assets’ book value to future net undiscounted cash flows that the assets are expected to generate. There have not been any impairment losses of long-lived assets through December 31, 2013.
Research and Development Costs	'
	Research and Development Costs
	All research and development costs are charged to expense as incurred. Such costs primarily consist of lab supplies, contract services, stock-based compensation expense, salaries and related benefits.
Acquired In-Process Research and Development Expense	'
	Acquired In-Process Research and Development Expense
	The Company has acquired and may continue to acquire the rights to develop and commercialize new drug candidates. The up-front payments to acquire a new drug compound, as well as future milestone payments, are immediately expensed as acquired in-process research and development provided that the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, have no alternative future use.
Income Taxes	'
	Income Taxes
	The provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 740-10, Uncertainty in Income Taxes, address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The Company has determined that it has no uncertain tax positions.
	The Company accounts for income taxes using the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts, using currently enacted tax rates.
	The Company has deferred tax assets, which are subject to periodic recoverability assessments. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company evaluates the recoverability of the deferred tax assets annually.
Revenue Recognition	'
	Revenue Recognition
	The Company’s inception to date revenues are generated primarily from three NIH and two U.S. Department of Treasury (or U.S. Treasury) grant awards and a feasibility study agreement, or the Collaboration Agreement, that the Company entered into with a third party in July 2010, and from revenues generated from Concortis. The revenue from the NIH and U.S. Treasury grant awards are based upon subcontractor and internal costs incurred that are specifically covered by the grant, and where applicable, a facilities and administrative rate that provides funding for overhead expenses. These revenues are recognized when expenses have been incurred by subcontractors or when the Company incurs internal expenses that are related to the grant.
	The revenue from the Collaboration Agreement is derived from the completion of certain development services and the reimbursement of certain development costs incurred to provide such development services. Revenue from upfront, nonrefundable service fees are recognized when earned, as evidenced by written acknowledgement from the collaborator, or other persuasive evidence that all service deliverables have been achieved, provided that the service deliverables are substantive and their achievability was not reasonably assured at the inception of the Collaboration Agreement. Any amounts received prior to satisfying the Company’s revenue recognition criteria are recorded as deferred revenue.
	Revenues from sales and services are generated from the sale of customized reagents and providing professional services. Reagents are used for preparing ADCs, these reagents include industrial standard cytotoxins, linkers, and linker-toxins. The professional services include providing synthetic expertise to customer’s synthesis by delivering them proprietary cytotoxins, linkers and linker-toxins and ADC service using industry standard toxin and antibodies provided by customers. Revenue is recognized when (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered, (iii) the price is fixed or determinable, and (iv) collectability is reasonably assured.
	The Company is obligated to accept from customers the return of products sold that are damaged or don’t meet certain specifications. The Company may authorize the return of products sold in accordance with the terms of its sales contracts, and estimates allowances for such amounts at the time of sale. The Company has not experienced any sales returns.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which establishes accounting for equity instruments exchanged for employee services. Under such provisions, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense, under the straight-line method, over the employee’s requisite service period (generally the vesting period of the equity grant).
	The Company accounts for equity instruments, including restricted stock or stock options, issued to non-employees in accordance with authoritative guidance for equity based payments to non-employees. Stock options issued to non-employees are accounted for at their estimated fair value determined using the Black-Scholes option-pricing model. The fair value of options granted to non-employees is re-measured as they vest, and the resulting increase in value, if any, is recognized as expense during the period the related services are rendered. Restricted stock issued to non-employees is accounted for at their estimated fair value as they vest.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. The Company is required to record all components of comprehensive income (loss) in the consolidated financial statements in the period in which they are recognized. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments and unrealized gains and losses on investments, are reported, net of their related tax effect, to arrive at comprehensive income (loss). For the years ended December 31, 2013 and 2012, the comprehensive loss was equal to the net loss.
Net Loss per Share	'
	Net Loss per Share
	Net loss per share is presented as both basic and diluted net loss per share. Basic net loss per share excludes any dilutive effects of options, shares subject to repurchase and warrants. Diluted net loss per share includes the impact of potentially dilutive securities. During 2013 and 2012, the Company had securities outstanding which could potentially dilute basic earnings per share in the future, but were excluded from the computation of diluted net loss per share, as their effect would have been anti-dilutive.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In February 2013, a new accounting standard was issued that amended existing guidance to improve the reporting of reclassifications out of accumulated other comprehensive income. The new standard requires the disclosure of significant amounts reclassified from each component of accumulated other comprehensive income and the income statement line items affected by the reclassification. The standard is effective prospectively for interim and annual periods beginning after December 15, 2012. We adopted this guidance as of January 1, 2013 and its adoption did not have an effect on our financial statements.

Significant_Accounting_Policie1

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Components of Outstanding Securities	'
	These outstanding securities consist of the following:
		Years Ended December 31,
		2013		2012
	Unvested Restricted Common stock subject to repurchase		—		13,458
	Outstanding options		1,047,300		419,600
	Outstanding warrants		221,850		8,000
	Weighted average exercise price of options	$	6.51	$	3.5

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment consisted of the following as of December 31, 2013 and 2012:
		December 31,
		2013			2012
	Furniture and fixtures	$	39,281		$	15,739
	Office equipment		80,764			23,039
	Lab equipment		3,186,735			1,855,220
	Leasehold improvements		65,679			65,679
			3,372,459			1,959,677
	Less accumulated depreciation and amortization		(932,606	)		(478,688	)
		$	2,439,853		$	1,480,989

Mergers_and_Acquisitions_Table

Mergers and Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Estimated Net Deferred Tax Liability	'
	The estimated net deferred tax liability was determined as follows ($ in thousands):
		IgDraSol			Sherrington			Concortis			Total
	Intangible license rights acquired	$	29,105		$	—		$	—		$	29,105
	Acquired in-process research and development					1,904						1,904
	Intangible customer relationships acquired		—			—			1,320			1,320
	Intangible technologies acquired		—			—			3,410			3,410
	Book basis		29,105			1,904			4,730			35,739
	Tax basis		55			218			(303	)		(30	)
	Difference		(29,050	)		(1,686	)		(5,033	)		(35,769	)
	Estimated tax rate		39.83	%		39.83	%		39.83	%		39.83	%
	Estimated net deferred tax liability	$	(11,571	)	$	(672	)	$	(2,005	)	$	(14,248	)
Schedule of Unaudited Pro Forma Combined Results	'
	The unaudited pro forma combined results are presented in thousands, except share and per share information.
		Years Ended December 31,
		2013			2012
	Total Revenues	$	3,850		$	584
	Loss from operations	$	(23,589	)	$	(4,853	)
	Net loss	$	(24,084	)	$	(4,845	)
	Net loss per share—basic and diluted	$	(1.60	)	$	(0.42	)
IgDraSol, Inc. [Member]	'
Summary of Purchase Price of Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the purchase price of the IgDraSol acquisition, the identified assets acquired and liabilities assumed at the acquisition date ($ in thousands):
	Assets acquired:
	Cash	$	126
	Prepaid expenses & other		45
	PP&E		121
	Intangible license rights		29,105
	Goodwill		11,571
	Total assets		40,968
	Liabilities assumed:
	Accounts payable		168
	Accrued expenses		124
	Net deferred tax liability		11,571
	Total liabilities		11,863
	Total purchase price	$	29,105
Concortis Biosystems, Corp. [Member]	'
Summary of Purchase Price of Identified Assets Acquired and Liabilities Assumed	'
	The following table summarizes the purchase price of the Concortis acquisition, the identified assets acquired and liabilities assumed at the acquisition date ($ in thousands):
	Assets acquired:
	Cash	$	302
	A/R, prepaid expenses & other		535
	PP&E		441
	Customer relationships		1,320
	Technologies		3,410
	Goodwill		11,798
	Total assets		17,806
	Liabilities assumed:
	Accounts payable and accrued expenses		1,118
	Net deferred tax liability		2,005
	Total liabilities		3,123
	Total estimated purchase price	$	14,683

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Schedule of Long-Term Debt and Unamortized Discount Balances	'
	Long-term debt and unamortized discount balances are as follows:
	Balance at December 31, 2012	$	—
	Face value of term loan		5,000,000
	Fair value of warrants		(214,680	)
	Accretion of debt discount		19,474
	Balance at December 31, 2013	$	4,804,794
Future Minimum Payments under Loan and Security Agreement	'
	Future minimum payments under the loan and security agreement are as follows:
	Year Ending December 31,
	2014	$	851,106
	2015		2,211,925
	2016		2,211,925
	2017		734,841
	Total future minimum payments		6,009,797
	Unamortized interest		(1,009,797	)
	Debt discount		(195,206	)
	Total minimum payment		4,804,794
	Current portion		(373,930	)
	Long-term debt	$	4,430,864

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value of Employee Stock Options	'
	The fair value of employee stock options was estimated at the grant date using the following assumptions:
		Years Ended December 31,
		2013			2012
	Weighted-average grant date fair value	$	8.19		$	7.25
	Dividend yield		—			—
	Volatility		87	%		103	%
	Risk-free interest rate		1.68	%		0.88	%
	Expected life of options		6.1 years			5.5 years
Summary of Common Stock Reserved for Future Issuance	'
	Common stock reserved for future issuance consists of the following at December 31, 2013:
	Common stock warrants outstanding under the TSRI License		8,000
	Common stock warrants outstanding under the Underwriters Agreement		182,600
	Common stock warrants outstanding under the loan and security agreement		31,250
	Common stock options outstanding under the EIP		3,200
	Authorized for future grant or issuance under the Stock Plan		293,400
	Issuable to former IgDraSol stockholders upon achievement of specified regulatory milestone		1,306,272
	Issuable under assignment agreement based upon achievement of certain milestones		80,000
			1,904,722
2009 Non-Employee Director Grants [Member]	'
Summary of Stock Option Activity	'
	The following table summarizes stock option activity as of December 31, 2012 and 2013, and the changes for the years then ended:
		Options			Weighted-
		Outstanding			Average
					Exercise Price
	Outstanding at December 31, 2011		4,800		$	1.12
	Options Granted		—			—
	Options Canceled		—			—
	Options Exercised		(1,600	)	$	1.12
	Outstanding at December 31, 2012		3,200		$	1.12
	Options Granted		—			—
	Options Canceled		—			—
	Options Exercised		—			—
	Outstanding, Vested and Exercisable at December 31, 2013		3,200		$	1.12
2009 Stock Incentive Plan [Member]	'
Summary of Stock Option Activity	'
	The following table summarizes stock option activity as of December 31, 2012 and 2013, and the changes for the years then ended:
		Options			Weighted-			Aggregate Intrinsic
		Outstanding			Average			Value
					Exercise Price
	Outstanding at December 31, 2011		113,100		$	3
	Options Granted		341,400		$	4
	Options Canceled		(28,900	)	$	3.75
	Options Exercised		(9,200	)	$	3.25
	Outstanding at December 31, 2012		416,400		$	3.75		$	54,750
	Options Granted		650,200		$	8.19
	Options Canceled		(15,200	)	$	3.92
	Options Exercised		(7,300	)	$	2.35
	Outstanding at December 31, 2013		1,044,100		$	6.52		$	1,859,880
	Vested and Exercisable at December 31, 2013		319,325		$	5.8		$	777,462

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Commitments And Contingencies Disclosure [Abstract]	'
Summary of Minimum Future Non-Cancelable Annual Operating Lease Obligations	'
	Minimum future non-cancelable annual operating lease obligations are as follows for the years ending December 31:
	2014	$	341,325
	2015		214,427
	2016		202,272
	2017		186,786
	2018		89,520
		$	1,034,330

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Summary of Components of Net Deferred Tax Assets	'
	Significant components of the Company’s net deferred tax assets are as follows as of December 31, 2013 and 2012:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforwards and credits	$	11,995,000		$	5,047,000
	Stock based compensation		506,000			97,000
	Accrued expenses and other		(202,000	)		(99,000	)
	Total deferred tax assets		12,299,000			5,045,000
	Less valuation allowance		(13,930,000	)		(5,045,000	)
	Net deferred tax assets		(1,631,000	)		—
	Deferred tax liabilities:
	Amortization of intangibles		(12,617,000	)		—
	Net deferred tax liabilities	$	(14,248,000	)	$	—

Nature_of_Operations_and_Busin2

Nature of Operations and Business Activities - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

95 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

Oct. 31, 2013

Sep. 30, 2013

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jul. 31, 2013

Feb. 28, 2013

Dec. 31, 2013

Oct. 31, 2013

Mar. 31, 2014

Sep. 30, 2013

Mar. 31, 2014

Oct. 09, 2013

Dec. 19, 2013

Dec. 31, 2013

Bank

QuikByte [Member]

Underwritten Public Offering [Member]

Subsequent Events [Member]

Lab equipment [Member]

Lab equipment [Member]

Sherrington Pharmaceuticals, Inc. [Member]

Concortis Biosystems, Corp. [Member]

Concortis Biosystems, Corp. [Member]

Bank

Subsequent Events [Member]

Reverse split of common stock

'

'

'

'Company completed a 1-for-25 reverse split of its common stock.

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split, common stock

'

'

'

0.04

'

0.04

'

'

'

'

'

'

'

'

'

'

Principal amount of loan agreement

'

$5,000,000

'

'

'

'

'

'

'

'

$12,500,000

'

'

'

'

'

Number of banks provided term loan

'

2

'

'

'

'

'

'

'

'

2

'

'

'

'

'

Equipment loan balance outstanding

'

'

'

'

'

'

'

'

'

'

'

762,361

5,000,000

'

'

'

Underwritten public offering shares of common stock

4,772,500

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwriters exercise over-allotment

622,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock price per share

$7.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from common stock issuance

34,600,000

'

'

37,701,369

5,934,031

53,152,820

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount of Convertible Promissory Notes

1,850,000

'

'

5,000,000

'

5,000,000

'

'

'

'

'

'

'

'

'

'

Interest rate

7.00%

7.95%

'

'

'

'

'

5.15%

'

'

7.95%

'

'

'

'

'

Debt converted into common stock

256,119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock convertible price per share

$7.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term loan maturity date

'

'

'

15-Apr-17

'

'

'

'

'

'

30-Sep-17

'

'

'

'

'

Proceeds from collaboration

'

'

'

'

'

'

'

'

'

'

30,000,000

'

'

'

'

'

Maximum amount of equity and other securities authorized to offer

'

'

'

'

'

'

100,000,000

'

'

'

'

'

'

'

'

'

Remaining amount of equity and other securities authorized to offer

65,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate of common shares

'

'

'

'

'

'

'

'

6,775,032

'

'

'

'

200,000

200,000

1,331,978

Common stock, shares outstanding

'

'

'

23,028,100

12,004,687

23,028,100

'

'

2,228,332

'

'

'

'

'

'

'

Cash received on merger

'

'

'

'

'

'

'

'

104,860

'

'

'

'

'

'

302,000

Warrant received to purchase aggregate of common stock - shares

'

31,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant received to purchase aggregate of common stock - exercise price

'

$8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock exercisable duration

'

'7 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt discount

'

'

'

$214,680

'

$214,680

'

'

'

'

'

'

'

'

'

'

Underwritten public offering shares of common stock

'

'

'

'

'

'

'

'

'

4,150,000

'

'

'

'

'

'

Significant_Accounting_Policie2

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended		95 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of assets	'19 years	'	'
Number of patent rights	1	0	'
Impairment losses of long-lived assets	0	'	'
Uncertain tax positions	0	'	0
Patents [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Amortization expense	'	'	3,750
License rights [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of assets	'15 years	'	'
Amortization expense	'	'	585,862
License rights outstanding	'	0	'
Technologies [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of assets	'19 years	'	'
Amortization expense	'	'	5,779
Acquired technology outstanding	'	0	'
Customer relationships [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Estimated useful lives of assets	'5 years	'	'
Amortization expense	'	'	8,679
Customer relationship outstanding	'	$0	'
Minimum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Property and equipment useful lives of assets	'3 years	'	'
Maximum [Member]	'	'	'
Significant Accounting Policies [Line Items]	'	'	'
Property and equipment useful lives of assets	'5 years	'	'

Significant_Accounting_Policie3

Significant Accounting Policies - Components of Outstanding Securities (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Weighted average exercise price of options	$6.51	$3.50
Unvested Restricted Common stock subject to repurchase [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Outstanding securities	'	13,458
Outstanding options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Outstanding securities	1,047,300	419,600
Outstanding warrants [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Outstanding securities	221,850	8,000

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Total	$3,372,459	$1,959,677
Less accumulated depreciation and amortization	-932,606	-478,688
Net of property, plant and equipment, total	2,439,853	1,480,989
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Total	39,281	15,739
Office equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Total	80,764	23,039
Lab equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Total	3,186,735	1,855,220
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Total	$65,679	$65,679

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended		95 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Property Plant And Equipment [Abstract]	'	'	'
Depreciation expense	$453,918	$293,302	$932,607

Significant_Agreements_and_Con1

Significant Agreements and Contracts - Additional Information (Detail) (USD $)

1 Months Ended

12 Months Ended

95 Months Ended

12 Months Ended

95 Months Ended

1 Months Ended

12 Months Ended

95 Months Ended

1 Months Ended

12 Months Ended

95 Months Ended

1 Months Ended

12 Months Ended

95 Months Ended

12 Months Ended

95 Months Ended

Jul. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jul. 31, 2011

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Jun. 30, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2013

Patents

Patents

Collaboration Agreement [Member]

Research and Development Expense [Member]

General and administrative expenses [Member]

General and administrative expenses [Member]

General and administrative expenses [Member]

Staph Grant Award [Member]

Staph Grant Award [Member]

Staph Grant Award [Member]

Staph Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

C Difficile Grant Award [Member]

Staph infections [Member]

Staph infections [Member]

Staph infections [Member]

Staph infections [Member]

U.S. Treasury Grants [Member]

U.S. Treasury Grants [Member]

Collaborative Agreements And Contracts [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash payment

'

'

'

'

'

$2,680,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Terminate notice of license

'

'60 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Patent prosecution and maintenance costs

'

'

'

'

'

'

65,574

41,835

192,919

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of the warrants to purchase Company common stock, issued

'

17,989

'

17,989

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average assumptions, risk-free interest rate

'

2.48%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average assumptions, dividend yield

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected term of warrants

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants volatility

'

102.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of patent rights

'

1

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option termination terms

'

'The option terminates on the latest of (i) twelve months from the effective date (June 30, 2013) or (ii) ten months from the date of filing of a first priority patent application as defined in the agreement.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period of grant

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'2 years

'

'

'

'2 years

'

'

'

'

'

Revenue grant as related costs and expenses incurred

'

451,773

583,774

2,023,846

223,453

'

'

'

'

'

0

119,379

600,000

'

143,940

335,579

592,717

'

307,833

128,816

436,649

394,480

394,480

Award of grant received for phase 1

'

'

'

'

'

'

'

'

'

'

600,000

'

600,000

'

600,000

'

600,000

'

'

'

'

'

'

Potential award of grant received for phase 1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

600,000

'

'

Antibody screening services for an upfront cash fee

$200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Mergers_and_Acquisitions_Addit

Mergers and Acquisitions - Additional Information (Detail) (USD $)	12 Months Ended			1 Months Ended		12 Months Ended	0 Months Ended		0 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Apr. 30, 2013	Mar. 31, 2013	Dec. 31, 2013	Oct. 09, 2013	Dec. 31, 2013	Dec. 19, 2013	Dec. 31, 2013
	License rights [Member]	Customer relationships [Member]	Technologies [Member]	IgDraSol, Inc. [Member]	IgDraSol, Inc. [Member]	IgDraSol, Inc. [Member]	Sherrington Pharmaceuticals, Inc. [Member]	Sherrington Pharmaceuticals, Inc. [Member]	Concortis Biosystems, Corp. [Member]	Concortis Biosystems, Corp. [Member]
								Patient
Loans At Acquisition Date [Line Items]	'	'	'	'	'	'	'	'	'	'
Cash payment in connection with IgDraSol merger	'	'	'	$200,000	'	$382,275	'	'	'	'
Initial services agreement amount	'	'	'	'	1,210,000	'	'	'	'	'
Purchase price of asset under assets purchase agreement	'	'	'	'	1,000,000	'	'	'	'	'
Development services agreement	'	'	'	1,721,193	'	'	'	'	'	'
Issuance of common stock in connection with IgDraSol merger, shares	'	'	'	'	'	3,006,641	200,000	'	200,000	1,331,978
Additional shares of common stock issued	'	'	'	'	'	1,306,272	'	'	'	'
Future amortization of intangible assets, annual rate	1,900,093	264,000	175,773	'	'	'	'	'	'	'
Amortization of intangible assets, maturity year	'2028	'2018	'2033	'	'	'	'	'	'	'
Total purchase price	'	'	'	'	'	'	1,697,600	'	'	14,683,000
Number of patients treated with terminal cancer pain	'	'	'	'	'	'	'	10	'	'
Bonus payable in 2013	'	'	'	'	'	'	'	'	'	1,000,000
Bonus payable in 2014	'	'	'	'	'	'	'	'	'	1,000,000
Bonus payable in 2015	'	'	'	'	'	'	'	'	'	1,000,000
Bonus payable in 2016	'	'	'	'	'	'	'	'	'	$1,000,000

Mergers_and_Acquisitions_Summa

Mergers and Acquisitions - Summary of Purchase Price of Identified Assets Acquired and Liabilities Assumed (Detail) (USD $)	Dec. 31, 2013
Assets acquired:	'
Intangible assets	$35,739,000
Goodwill	24,040,966
Liabilities assumed:	'
Net deferred tax liability	14,248,000
Customer relationships [Member]	'
Assets acquired:	'
Intangible assets	1,320,000
Technologies [Member]	'
Assets acquired:	'
Intangible assets	3,410,000
License rights [Member]	'
Assets acquired:	'
Intangible assets	29,105,000
Concortis Biosystems, Corp. [Member]	'
Assets acquired:	'
Cash	302,000
A/R, prepaid expenses & other	535,000
PP&E	441,000
Intangible assets	4,730,000
Goodwill	11,798,000
Total assets	17,806,000
Liabilities assumed:	'
Accounts payable and accrued expenses	1,118,000
Net deferred tax liability	2,005,000
Total liabilities	3,123,000
Total estimated purchase price	14,683,000
Concortis Biosystems, Corp. [Member] | Customer relationships [Member]	'
Assets acquired:	'
Intangible assets	1,320,000
Concortis Biosystems, Corp. [Member] | Technologies [Member]	'
Assets acquired:	'
Intangible assets	3,410,000
IgDraSol, Inc. [Member]	'
Assets acquired:	'
Cash	126,000
A/R, prepaid expenses & other	45,000
PP&E	121,000
Intangible assets	29,105,000
Goodwill	11,571,000
Total assets	40,968,000
Liabilities assumed:	'
Accounts payable	168,000
Accrued expenses	124,000
Net deferred tax liability	11,571,000
Total liabilities	11,863,000
Total purchase price	29,105,000
IgDraSol, Inc. [Member] | License rights [Member]	'
Assets acquired:	'
Intangible assets	$29,105,000

Mergers_and_Acquisitions_Sched

Mergers and Acquisitions - Schedule of Estimated Net Deferred Tax Liability (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Income Tax Contingency [Line Items]	'
Book basis	$35,739
Difference	-35,769
Estimated tax rate	39.83%
Estimated net deferred tax liability	-14,248
Tax basis [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	-30
License rights [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	29,105
Acquired in-process research and development [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	1,904
Customer relationships [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	1,320
Technologies [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	3,410
IgDraSol, Inc. [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	29,105
Difference	-29,050
Estimated tax rate	39.83%
Estimated net deferred tax liability	-11,571
IgDraSol, Inc. [Member] | Tax basis [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	55
IgDraSol, Inc. [Member] | License rights [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	29,105
Sherrington Pharmaceuticals, Inc. [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	1,904
Difference	-1,686
Estimated tax rate	39.83%
Estimated net deferred tax liability	-672
Sherrington Pharmaceuticals, Inc. [Member] | Tax basis [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	218
Sherrington Pharmaceuticals, Inc. [Member] | Acquired in-process research and development [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	1,904
Concortis Biosystems, Corp. [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	4,730
Difference	-5,033
Estimated tax rate	39.83%
Estimated net deferred tax liability	-2,005
Concortis Biosystems, Corp. [Member] | Tax basis [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	-303
Concortis Biosystems, Corp. [Member] | Customer relationships [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	1,320
Concortis Biosystems, Corp. [Member] | Technologies [Member]	'
Income Tax Contingency [Line Items]	'
Book basis	$3,410

Mergers_and_Acquisitions_Sched1

Mergers and Acquisitions - Schedule of Unaudited Pro Forma Combined Results (Detail) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]	'	'
Total Revenues	$3,850	$584
Loss from operations	-23,589	-4,853
Net loss	($24,084)	($4,845)
Net loss per share-basic and diluted	($1.60)	($0.42)

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2013	Oct. 31, 2013	Feb. 28, 2013	Dec. 31, 2012
	Bank
Debt Disclosure [Abstract]	'	'	'	'	'
Long-term debt	'	$4,804,794	'	$875,888	'
Fixed rate interest accrued on the initial outstanding advance	7.95%	'	7.00%	5.15%	'
Principal amount of loan agreement	5,000,000	'	'	'	'
Number of banks provided term loan	2	'	'	'	'
Term loan maturity date	'	15-Apr-17	'	'	'
Warrant received to purchase aggregate of common stock - shares	31,250	'	'	'	'
Warrant received to purchase aggregate of common stock - exercise price	$8	'	'	'	'
Exercisable period for warrants	'7 years	'	'	'	'
Debt discount	'	214,680	'	'	'
Minimum percentage of pre-payment fees	'	1.00%	'	'	'
Maximum percentage of pre-payment fees	'	3.00%	'	'	'
Final fee	'	$200,000	'	'	'

Debt_Schedule_of_LongTerm_Debt

Debt - Schedule of Long-Term Debt and Unamortized Discount Balances (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Oct. 31, 2013	Feb. 28, 2013
Debt Disclosure [Abstract]	'	'	'
Beginning balance	'	'	$875,888
Face value of term loan	5,000,000	1,850,000	'
Fair value of warrants	-214,680	'	'
Accretion of debt discount	19,474	'	'
Ending balance	$4,804,794	'	$875,888

Debt_Future_Minimum_Payments_u

Debt - Future Minimum Payments under Loan and Security Agreement (Detail) (USD $)	Dec. 31, 2013	Feb. 28, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]	'	'	'
2014	$851,106	'	'
2015	2,211,925	'	'
2016	2,211,925	'	'
2017	734,841	'	'
Total future minimum payments	6,009,797	'	'
Unamortized interest	-1,009,797	'	'
Debt discount	-195,206	'	'
Total minimum payment	4,804,794	875,888	'
Current portion	-373,930	'	'
Long-term debt	$4,430,864	'	'

Stockholders_Equity_Common_Sto

Stockholders' Equity (Common Stock and Related Party Transaction) (Detail) (USD $)

1 Months Ended

12 Months Ended

95 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

Oct. 31, 2013

Jan. 31, 2013

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2013

Sep. 30, 2013

Feb. 28, 2013

Dec. 31, 2013

Sep. 30, 2009

31-May-12

Oct. 31, 2013

Feb. 28, 2006

Mar. 31, 2009

Mar. 31, 2013

Dec. 31, 2010

Dec. 31, 2011

Sep. 30, 2009

Jun. 30, 2009

Dec. 31, 2011

Oct. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Mar. 31, 2009

Underwriters [Member]

QuikByte [Member]

Hongye SD Group LLC [Member]

Convertible Promissory Notes [Member]

2006 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

Private placement transaction [Member]

Private placement transaction [Member]

Private placement transaction [Member]

Private placement transaction [Member]

Private placement transaction [Member]

Stock Purchase Agreement [Member]

Underwritten Public Offering [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Restricted stock [Member]

QuikByte [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

OPKO [Member]

Unrestricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock to founders under 2006 equity incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,077,493

'

'

'

'

'

'

'

'

10,000

'

'

'

'

'

Gross proceeds from common stock issuance

$34,600,000

'

'

$37,701,369

$5,934,031

'

'

'

$53,152,820

'

'

'

'

'

'

$400

'

'

'

'

'

'

'

'

'

'

'

'

'

$10

Shares issued to consultants under 2009 equity incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

296,154

'

'

'

'

'

'

'

'

'

'

'

'

40,775

Aggregate gross proceeds

'

'

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

291

6,418,495

3,600,000

'

1,999,620

'

2,000,000

'

'

'

'

'

'

'

Note receivable for common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30

Company issued shares common stock to OPKO

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,360,611

'

'

'

'

'

'

'

'

Per share value

'

'

$4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.50

$3.50

'

$1.12

$0.98

$4

'

'

'

'

'

'

'

Aggregate gross proceeds to OPKO from stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,300,000

'

'

'

'

'

'

'

'

Related stock issuance cost

'

'

'

'

65,969

28,999

159,905

'

'

'

'

'

'

'

'

'

'

'

159,905

'

'

25,999

'

'

'

'

'

'

'

'

Issuance of common stock for cash, net of issuance costs, shares

4,772,500

'

1,500,000

'

'

'

'

'

'

'

'

'

'

250,000

'

'

'

1,426,406

1,028,686

'

1,785,375

'

500,000

'

'

1,500,000

500,000

1,028,686

'

'

Issuance of common stock to former QuikByte stockholders in connection with the Merger, shares

'

'

'

'

'

'

'

'

'

'

'

'

442,958

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

442,958

'

Costs incurred associated with the Merger

'

'

'

'

'

'

'

168,767

'

'

'

'

168,767

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reduction of stock issuance costs accrued in December 2010

'

'

'

'

'

80,039

'

'

'

'

'

'

'

'

'

'

'

'

'

80,039

'

'

'

'

'

'

'

'

'

'

Number of shares issued for purchase of patent rights

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Value of common stock issued for purchase of patent rights

'

40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Underwritten public offering shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,150,000

'

'

'

'

'

'

Common stock price per share

$7.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of additional common shares granted to purchase under over-allotment option

622,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of common shares to be purchased under warrants

'

'

'

'

'

'

'

'

'

'

'

182,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase price of common stock warrants issued

'

'

'

'

'

'

'

'

'

'

'

100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant agreement exercisable and expiration description

'

'

'

'

'

'

'

'

'

'

'

'Warrant agreement is exercisable, in whole or in part, commencing on a date which is one (1) year after the effective date of the Registration Statement and expiring on the five-year anniversary of the effective date of the Registration Statement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial exercise price per share of common stock under warrants

'

'

'

9.0625

'

'

'

'

9.0625

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants to percentage of initial public offering price of shares

'

'

'

125.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering price per share

'

'

'

$7.25

'

'

'

'

$7.25

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate principal amount of Convertible Promissory Notes

1,850,000

'

'

5,000,000

'

'

'

'

5,000,000

'

'

'

'

'

1,850,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Bear interest rate

7.00%

'

'

'

'

'

'

'

'

7.95%

5.15%

'

'

'

7.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest

$6,832

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt converted into common stock

256,119

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Stock_Ince

Stockholders' Equity (Stock Incentive Plans) (Detail) (USD $)

1 Months Ended

12 Months Ended

95 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Apr. 26, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Sep. 30, 2009

Dec. 13, 2013

Feb. 28, 2009

Mar. 31, 2009

Jan. 31, 2011

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Stock Incentive Plan [Member]

2009 Non-Employee Director Grants [Member]

2009 Non-Employee Director Grants [Member]

2009 Non-Employee Director Grants [Member]

2009 Non-Employee Director Grants [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

2009 Equity Incentive Plan [Member]

Outstanding options [Member]

Outstanding options [Member]

Restricted stock [Member]

Unvested restricted stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock reserved for issuance under 2009 equity incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

8,000

'

400,000

'

'

Shares issued to consultants under 2009 equity incentive plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

296,154

'

Aggregate gross proceeds

$6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$291

'

Unvested shares of restricted common stock repurchased by the company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

44,166

Price per share of unvested shares of restricted common stock repurchased by the company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$43

Restricted shares vesting period under 2009 equity incentive plan

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'4 years

'

'

'

Shares Available for Further Grant under 2009 Non-Employee Director Grants

'

'

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

Outstanding options vesting anniversary period

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

Minimum exercisable term for stock options

'

'

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

Maximum term of options granted under stock plan

'

'

'

'

'10 years

'

'

'

'

'10 years

'

'

'

'

'

'

'

Option outstanding

'

'

'

'

1,044,100

'

416,400

113,100

'

3,200

3,200

4,800

'

'

'

'

'

Common stock, shares authorized

'

750,000,000

750,000,000

750,000,000

'

1,360,000

'

'

'

'

'

'

'

'

'

'

'

Employee option grants vested

'

'

'

'

25.00%

'

'

'

'

'

'

'

'

'

'

'

'

2009 Stock Incentive Plan common stock reserved for issuance description

'

'

'

'

'In addition, this amount will be automatically increased annually on the first day of each fiscal year by the lesser of: (i) 1% of the aggregate number of shares of the Company's common stock outstanding on the last day of the immediately preceding fiscal year, (ii) 200,000 shares, or (iii) an amount approved by the administrator of the Stock Plan.

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares for increase in shares reserved for issuance under stock plan

'

'

'

'

200,000

'

'

'

'

'

'

'

'

'

'

'

'

Stock options vesting rights under 2009 stock incentive plan

'

'

'

'

'

'

'

'

'Employee option grants will generally vest 25% on each anniversary of the original vesting date over four years.

'

'

'

'

'

'

'

'

Employee stock-based compensation recorded as operating expenses

'

1,545,038

324,958

1,963,854

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to the employee options

'

'

'

'

3,752,673

'

'

'

'

'

'

'

'

'

'

'

'

Period for recognized compensation cost

'

'3 years 3 months 18 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation for non-employees

'

$243,696

$538,169

$1,291,519

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Summary_of

Stockholders' Equity - Summary of Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Options Exercised, Weighted Average Exercise Price	$6.51	$3.50
2009 Non-Employee Director Grants [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Option Outstanding Beginning Balance	3,200	4,800
Weighted Average Exercise Price, Beginning Balance	$1.12	$1.12
Options Granted, Options Outstanding	'	'
Options Canceled, Options Outstanding	'	'
Options Exercised, Options Outstanding	'	-1,600
Option Outstanding Ending Balance	3,200	3,200
Options Outstanding, Outstanding Vested and Exercisable at December 31, 2013	3,200	'
Options Granted, Weighted Average Exercise Price	'	'
Options Canceled, Weighted Average Exercise Price	'	'
Options Exercised, Weighted Average Exercise Price	'	$1.12
Weighted Average Exercise Price, Ending Balance	'	$1.12
Weighted Average Exercise Price, Outstanding Vested and Exercisable at December 31, 2013	$1.12	'
2009 Stock Incentive Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'	'
Option Outstanding Beginning Balance	416,400	113,100
Weighted Average Exercise Price, Beginning Balance	$3.75	$3
Options Granted, Options Outstanding	650,200	341,400
Options Canceled, Options Outstanding	-15,200	-28,900
Options Exercised, Options Outstanding	-7,300	-9,200
Option Outstanding Ending Balance	1,044,100	416,400
Options Outstanding, Outstanding Vested and Exercisable at December 31, 2013	319,325	'
Options Granted, Weighted Average Exercise Price	$8.19	$4
Options Canceled, Weighted Average Exercise Price	$3.92	$3.75
Options Exercised, Weighted Average Exercise Price	$2.35	$3.25
Weighted Average Exercise Price, Ending Balance	$6.52	$3.75
Weighted Average Exercise Price, Outstanding Vested and Exercisable at December 31, 2013	$5.80	'
Aggregate Intrinsic Value, Beginning Balance	$54,750	'
Aggregate Intrinsic Value, Ending Balance	1,859,880	54,750
Aggregate Intrinsic Value, Vested and Exercisable at December 31, 2013	$777,462	'

Stockholders_Equity_Fair_Value

Stockholders' Equity - Fair Value of Employee Stock Options (Detail) (Employee Stock Option [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Stock Option [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]	'	'
Weighted-average grant date fair value	$8.19	$7.25
Dividend yield	'	'
Volatility	87.00%	103.00%
Risk-free interest rate	1.68%	0.88%
Expected life of options	'6 years 1 month 6 days	'5 years 6 months

Stockholders_Equity_Summary_of1

Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Detail)	Dec. 31, 2013
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	1,904,722
IgDraSol, Inc. [Member]	'
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	1,306,272
TSRI [Member]	'
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	8,000
Underwriters Agreement [Member]	'
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	182,600
Loan and Security Agreement [Member]	'
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	31,250
Equity Incentive Plan [Member]	'
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	3,200
Stock Plan [Member]	'
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	293,400
Assignment Agreement [Member]	'
Class of Stock [Line Items]	'
Total common stock reserved for future issuance	80,000

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	12 Months Ended		95 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
	sqft		sqft
Other Commitments [Line Items]	'	'	'
Additional laboratory space adjacent to our corporate office	3,216	'	3,216
Lease expiration date for additional rental space	'2017-04	'	'
Option in additional rental space operating lease for extend term	'5 years	'	'
Security deposit	$50,479	'	$50,479
Rental expense paid	$198,259	$128,300	$533,443
Corporate office and laboratory space [Member]	'	'	'
Other Commitments [Line Items]	'	'	'
Leased office space	12,000	'	12,000
Non-cancelable operating lease amended, expires	30-Sep-14	'	'
Non-cancelable operating lease extend term	'4 years	'	'
Laboratory and office space [Member]	'	'	'
Other Commitments [Line Items]	'	'	'
Leased office space	6,350	'	6,350
Non-cancelable operating lease amended, expires	30-Jun-18	'	'
Office space [Member]	'	'	'
Other Commitments [Line Items]	'	'	'
Leased office space	2,400	'	2,400
Non-cancelable operating lease amended, expires	31-Mar-15	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Summary of Minimum Future Non-Cancelable Annual Operating Lease Obligations (Detail) (USD $)	Dec. 31, 2013
Leases [Abstract]	'
2014	$341,325
2015	214,427
2016	202,272
2017	186,786
2018	89,520
Total	$1,034,330

Income_Taxes_Summary_of_Compon

Income Taxes - Summary of Components of Net Deferred Tax Assets (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carryforwards and credits	$11,995,000	$5,047,000
Stock based compensation	506,000	97,000
Accrued expenses and other	-202,000	-99,000
Total deferred tax assets	12,299,000	5,045,000
Less valuation allowance	-13,930,000	-5,045,000
Net deferred tax assets	-1,631,000	'
Deferred tax liabilities:	'	'
Amortization of intangibles	-12,617,000	'
Net deferred tax liabilities	($14,248,000)	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Operating Loss And Tax Credit Carryforwards [Line Items]	'	'
Valuation allowance	$13,930,000	$5,045,000
Ownership change percent	50.00%	'
Foreign Tax Authority [Member]	'	'
Operating Loss And Tax Credit Carryforwards [Line Items]	'	'
Net operating loss carryforwards	28,138,000	'
Foreign Tax Authority [Member] | Research Tax Credit Carryforward [Member]	'	'
Operating Loss And Tax Credit Carryforwards [Line Items]	'	'
Research and development credits	541,000	'
State and Local Jurisdiction [Member]	'	'
Operating Loss And Tax Credit Carryforwards [Line Items]	'	'
Net operating loss carryforwards	25,732,000	'
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]	'	'
Operating Loss And Tax Credit Carryforwards [Line Items]	'	'
Research and development credits	$586,000	'

401k_Plans_Additional_Informat

401(k) Plans - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013
Compensation And Retirement Disclosure [Abstract]	'
Contribution made in 401(K) defined benefit plan	$0

Subsequent_Events_Additional_I

Subsequent Events - Additional Information (Detail) (USD $)	12 Months Ended				1 Months Ended
	Dec. 31, 2013	Oct. 31, 2013	Sep. 30, 2013	Feb. 28, 2013	Mar. 31, 2014	Mar. 31, 2014
			Bank		Subsequent Events [Member]	Subsequent Events [Member]
					Bank	New Term Loan [Member]
						Bank
Subsequent Event [Line Items]	'	'	'	'	'	'
Principal amount of loan agreement	'	'	$5,000,000	'	$12,500,000	'
Loan interest rate	'	7.00%	7.95%	5.15%	7.95%	7.95%
Term loan payment of principal and interest description	'	'	'	'	'	'The Company will make interest only payments on the outstanding amount of the loan on a monthly basis until October 1, 2014, after which equal monthly payments of principal and interest are due until the loan maturity date of September 30, 2017.
Term loan maturity date	15-Apr-17	'	'	'	30-Sep-17	30-Sep-17
Number of banks provided term loan	'	'	2	'	2	2
Warrants right to purchase common stock in connection with term loan	'	'	'	'	34,642	'
Warrant right exercise price	9.0625	'	'	'	12.99	'
Warrant right exercise term	'	'	'	'	'7 years	'
Proceeds from collaboration	'	'	'	'	$30,000,000	'